Podcasts about k23

Ramadan Kareem! ☪️Thanks for joining us for this SPECIAL Ramadan episode of Lagos Meets London

We are joined this week by Dr. Meredith Gansner. Dr. Gansner is a child psychiatrist at Boston Children's Hospital and an instructor of Psychiatry at Harvard Medical School, specializing in high-risk digital media use in teens. She has received multiple research grants, including a K23 career development award from the National Institute on Drug Abuse, and she is an active member of the American Academy of Child and Adolescent Psychiatry media committee. Her first book, Teen Depression Gone Viral, explores the challenges of treating adolescent depression in the digital age. In this episode, Dr. Meredith Gansner discusses depression in teens, something that has been on the rise especially in today's digital age. She sheds some light on how adolescent depression often looks different from adult depression, sometimes showing up as irritability, aggression, or even physical symptoms like headaches and stomach pain. She helps us break down why it's so important for parents to recognize these signs early on and seek professional support instead of just dismissing them as typical teenage behavior. Dr. Gansner also examines the relationship between social media and mental health. While some teens find support online, others are exposed to harmful content that can reinforce unhealthy coping mechanisms and worsen or even cause poor mental health. She offers some practical advice on improving digital media literacy, setting boundaries, and developing safety plans to help young people engage with the internet and social media in a way that is not detrimental to their well-being. Dr. Gansner also discusses effective treatments for teen depression, stressing a multi-faceted approach including lifestyle changes, therapy, and medication when appropriate. She also clarifies the differences between suicidal thoughts and non-suicidal self-injury, offering guidance on how parents and caregivers can respond with the right level of support. With a focus on family-based strategies, this conversation with Dr. Meredith Gansner helps provide insightful information for anyone looking to strengthen emotional resilience in today's teenagers!   Show Notes: [2:13] - Dr. Gansner reflects on initially feeling optimistic about addressing mental health in youth online but grew frustrated. [5:56] - The youth mental health crisis peaked during COVID and remains a pressing issue. [6:23] - Depression is a physiological illness with many contributing risk factors. [8:03] - Teen depression often manifests as irritability or anger, making it harder for parents to recognize. [11:29] - Some children with depression experience physical symptoms like headaches or stomachaches. [13:08] - Hear about the inspiration behind the title of Dr. Gansner's book. [15:53] - Social media spreads both helpful and harmful information about depression, requiring careful oversight and guidance. [18:32] - Social media can both support and worsen teens' mental health, creating harmful echo chambers. [19:26] - Dr. Gansner feels that rather than banning social media, teaching digital literacy can help children take on harmful content. [21:40] - Teaching teens responsible internet use with guidance, like learning to drive, helps ensure safer engagement. [24:43] - What are some of the best ways to treat depression in teens? [27:31] - Parents often struggle to differentiate suicidal thoughts from non-suicidal self-injury in teens. [28:05] - Dr. Gansner explains that non-suicidal self-injury involves self-harm without suicidal intent, often as a distress signal or coping mechanism. [31:21] - Simply telling teens to "just stop" self-harm can lead to shame, worsening depression and leading to a harmful cycle. [33:17] - Improving sleep is important for teens' emotional resilience, helping prevent impulsive decisions and risky behaviors. [36:58] - Parents limiting their own screen use helps depressed teens feel supported and less isolated. [38:38] - Be sure to get Dr. Gansner's book at a discounted price here! Links and Related Resources: Episode 131: Cognitive Behavior Therapy for Kids and Teens with Dr. Shadab Jannati Episode 148: How Sleep Affects Academic Performance and Mood Episode 160: The Sleep-Deprived Teen with Lisa Lewis Episode 169: The Science of Exercise and the Brain with Dr. John Ratey Discount on Teen Depression Gone Viral   Connect with Us: Get on our Email List Book a Consultation Get Support and Connect with a ChildNEXUS Provider Register for Our Self-Paced Mini Courses: Support for Parents Who Have Children with ADHD, Anxiety, or Dyslexia    Connect with Dr. Meredith Gansner: Boston Children's Hospital - Meredith Gansner  

New kilns bring lots of excitement to the studio, but also a few questions. Should I calibrate my thermocouple? And, Do I need to adjust my firing rate to my new elements? This episode the gang talk about new kilns, ASTM standards for ware, and the difference between K23 and K26 soft bricks. They also start the show discussing testing methods for glaze durability. Do you have questions or need advice on glazes? Drop us a line at ForFluxSakePodcast@gmail.com and you could be featured on an upcoming show.   This week's episode features the following topics: Thermocouple, New Kiln, commercial kiln, K26, K23, bricks   Today's episode is brought to you by Cornell Studio Supply and the Rosenfield Collection of Ceramic Art.  

Noticiero de Martí Noticias presenta un resumen de las noticias más importantes de Cuba y el mundo. Titulares: | Cubanos critican apertura de supermercado que solo acepta dólares | El lujoso rascacielos K23 genera cuestionamientos | Los niños cubanos pasan otro Día de Reyes sin juguetes | El Congreso de Estados Unidos certifica hoy la victoria electoral de Donald Trump | El gobierno de Maduro amenaza al opositor Edmundo González si regresa a Venezuela | Justin Trudeau renuncia como primer ministro de Canadá, entre otras noticias.

El hotel ubicado en las intercepciones de las calles 23 y K en el vedado capitalino, se convierte en la edificación más alta de la Isla y será inaugurado en momentos que Cuba vive su peor crisis económica en más de seis décadas.

Una discusión a fondo de las principales noticias del acontecer diario de Cuba y el mundo, con la conducción de los periodistas Amado Gil y José Luis Ramos | Hoy, en la Tertulia de Las Noticias Como Son: | Gran diversidad': un perfil oficialista defiende la nueva tienda en dólares, mientras el régimen calla | Llueven críticas por supermercado en Cuba que solo acepta dólares: "un inaudito acto de villanía" | K23, rascacielos de La Habana se alza en medio de una ciudad en ruinas | Otro Día de Reyes sin juguetes para los niños cubano | Invitados: Luz Escobar, periodista de DDC y Pedro González Reinoso, escritor y periodista independiente.

JCO PO author Dr. Alok A. Khorana, MD, FASCO, Professor of Medicine, Cleveland Clinic and Case Comprehensive Cancer Center, shares insights into the JCO PO article, “Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers.” Host Dr. Rafeh Naqash and Dr. Khorana discuss how multiomic analysis shows higher FGFR2 fusions and immunotherapy marker variations in early-onset biliary cancer. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO POarticles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.  Today, we are joined by Dr. Alok A. Khorana, Professor of Medicine at the Cleveland Clinic and Case Comprehensive Cancer Center, and also the Senior Author of the JCO Precision Oncology article titled, “Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers.”  At the time of this recording, our guest disclosures will be linked in the transcript.  Dr. Khorana, it's an absolute pleasure to have you here today, and welcome to the podcast. Dr. Alok A. Khorana: Thank you. It's an absolute pleasure to be here and thank you for highlighting this article. Dr. Rafeh Naqash: Absolutely. We're going to talk about science, obviously, and a few other things. So to start off, for the sake of our audience, which comprises academicians and community oncologists as well as trainees, can you tell us a little bit about biliary tract cancers, what we have learned over the last decade or so, where the standard of treatment currently lies. And then we can dive into the article that you published. Dr. Alok A. Khorana: As many of you who treat GI cancers know, biliary tract cancers for a long period of time were sort of the orphan cancer in the GI cancer world. They're not nearly as common as, say, pancreatic cancer, and certainly not as common as colorectal cancer. They're sort of also, in this weird ‘no man's land' between well known sort of adjuvant therapy trials in pancreatic cancer or colorectal cancer, but because they're not as high in volume, there weren't really large trials done in this population. What's really changed in the past decade, especially, has been the slow but sure realization that biliary tract cancers are in fact a target rich cancer, almost similar to what you would see with lung cancer, and that's only a slight exaggeration. And in some studies, as many as up to 40% of patients with biliary tract cancers can have something that's targetable. And that's really revolutionized the way we think of biliary tract cancers. It also separated this field from pancreatic cancer where formerly the two used to be lumped together, and even within biliary tract cancers, we are now slowly realizing that there are differences between intrahepatic, extrahepatic and gallbladder cancers. Big change is really afoot in this field, particularly with the identification of mutation directed targets. Dr. Rafeh Naqash: Thank you for that explanation.  Now, another question I have is, although I don't see any GI cancers, but I have good colleagues of mine at our cancer center who see a lot of GI pancreatic/biliary cancers, and one of the things that comes up in our molecular tumor board often is how certain cancers of unknown primary end up being identified or categorized as biliary tract cancers based on NGS. And again, the uptake for these NGS is perhaps isn't optimal in the field yet, but in your practice, how do you approach situations like that? Do you use NGS in certain cases where the tissue of origin or the patterns of the mutations indicate that this might be biliary tract cancer and then treat the patient accordingly?  Dr. Alok A. Khorana: Yeah, that's true. And that's certainly how I approach things, and I would say even in my own personal practice, that has been a change. I was a little bit skeptical about the benefit of sort of tissue of origin type of testing in carcinoma of unknown, primarily, especially if you can sort of narrow it down to one or other area of the GI tract. But with the identification of sort of targeted subpopulations, especially of biliary tract cancer, I think it's become imperative. And I know we're going to get into the paper, but if you want to learn nothing else from this 20, 25 minute podcast, one lesson I just want to make sure everybody gets is that any patient with biliary tract cancer should have NGS done as soon as possible. Dr. Rafeh Naqash: Thank you for highlighting that important aspect.  Now, going to the topic at hand, what was the driving factor? I've heard a lot about colorectal cancers, early onset versus later onset. What was the reason that you looked at biliary tract cancers? Is that something that you've seen on a rise as far as early onset biliary tract cancers is concerned?  Dr. Alok A. Khorana: Yeah. So we got into this subject also from starting out at colorectal cancer. And as you know, and I'm sure most of your audience knows, there's been a lot of literature out there over the past five, six, seven years suggesting and then documenting and then sort of proving and reproving that colorectal cancer is on the rise, and especially in people younger than age 50. And even in that population, it's on the rise in two different subpopulations, people in their 20s and 30s and then people in their 40s that are close to the screening colonoscopy rates. That's been investigated heavily. We still don't fully understand why that's happening, but it's not restricted to the United States. It's a worldwide phenomenon. You can see it in the United States, in North America. You can see it in western Europe, but you can also see it in many Asian countries with specific sort of subpopulations. For instance, in some countries, men are more likely to have early onset cancers.   And then a newer finding that sort of emerged over the past couple of years is that this early onset increase in cancers is not just restricted to colorectal cancer, although that's the one that sticks out the most, but in fact, is widespread across a bunch of different types of cancers. In my own research program, we had gotten into a sort of better understanding of early onset colorectal cancer a couple of years ago, driven primarily by the sort of patients that I saw in my practice. And it's just, as you know, when you have a couple of those heartbreaking cases and they're just impossible to forget, and it sort of just drives your attention, and then you want to do something to help them. And if you can't help them personally, then you want to do something that can change the field so that more of these patients are not coming in your clinic next year or the year after.  So a couple years ago, at the Cleveland Clinic where I practice, we created a center for young onset cancers, and at the time it was primarily focused on colorectal cancer. But as we are getting into colorectal cancer, we realize that beyond colorectal cancer, we are also starting to see more younger people with other cancers, including pancreas cancer, including gastric cancer, and including bile duct cancers. And we realized that because so much attention was being focused on colorectal, that maybe we should also be paying a little bit of attention to what was happening in this space. I want to, for your listeners, point out that the problem in bile duct cancers is not to the same degree as you see in colorectal cancer. Just a couple numbers to sort of, to set this in perspective: about 5%, 7% of bile duct cancers are young onset - it's not a huge proportion - 90%+ percent of patients are not young onset. But the impact on society, the impacts on those providing care, is obviously substantial for younger patients. And it is true that even though the proportion of patients is not that high, the incidence is rising.   And there's a very nice study done a couple of years ago and published that looked at what the cancers are that are rising at the highest rates. And bile duct cancer and gallbladder cancers were listed amongst the two with the highest rate, so about an 8% rate per year of increase. And so that's really what drove our interest was, as we're seeing early onset bile duct cancers, it's rising year by year, and what is this disease? Is it the same as you see in sort of the average patient with bile duct cancer? Is it different? How do we characterize it? How do we understand it? What are some of the causes precipitating it? And so that's what led us to sort of one of the investigations that we've documented in this paper.  Dr. Rafeh Naqash: Excellent.   So, talking about this paper, again, can you describe the kind of data that you use to understand the molecular differences and also look at potential immune signatures, etc., differences between the groups? Dr. Alok A. Khorana: Yeah. So the objective in this paper was to look at genomic differences between early onset and usual onset, or average onset biliary tract cancers. And this sort of followed the paradigm that's already been established for early onset colorectal cancer, where you take a bunch of people with early onset disease, a bunch of patients with average onset or usual onset disease, and then look at the profiling of the tumors. And we've done this for genomics, we've done this for microbiomics, we've done it for metabolomics. And the lessons we've learned in colorectal cancer is that, in many ways, the profiles are actually quite substantially different. And you can almost think of them as diseases of the same organ, but caused by different processes, and therefore leading to different genotypes and phenotypes and microbiomes. We had absorbed that lesson from colorectal cancer, and we wanted to replicate it in this type of cancer.  But as we discussed earlier, this is a relatively rare cancer, not that many cases per year. For colorectal, we could do a single institution or two institution studies. But for this, we realized we needed to reach out to a source of data that would have access to large national data sets. We were happy to collaborate with Caris Life Sciences. Caris, many of you might know, is a provider of genomics data, like many other companies, and they house this data, and they had the age categorization of patients less than 50, more than 50. And so we collaborated with investigators at Caris to look at all the specimens that had come in of bile duct cancers, identified some that were young onset and some that were older onset. It was roughly about 450 patients with the early onset or young onset, and about 5000 patients with usual onset cases. And then we looked at the genomics profiling of these patients. We looked at NGS, whole exome sequencing, whole transcriptome sequencing, and some immunohistochemistry for usual, like PDL-1 and MSI High and things like that. And the purpose was to say, are there differences in molecular profiling of the younger patient versus the older patient? And the short answer is yes, we did find substantial differences, and very crucial for providers treating these patients is that we found a much higher prevalence of FGFR2 fusion. And that's important because, as I'm sure you've heard, there's a ton of new drugs coming out that are targeting specifically FGFR fusion in this and other populations. And hence my statement at the outset saying you've got to get NGS on everybody, because especially younger patients seem to have higher rates of some of these mutations.  Dr. Rafeh Naqash: Excellent. You also looked at the transcriptome, and from what I recollect, you identified that later onset tumors had perhaps more immune favorable tumor microenvironment than the early onset. But on the contrary, you did find that FGFR2 early onset had better survival. So how do you connect the two? Is there an FGFR link, or is there an immune signature link within the FGFR cohort for early onset that could explain the differences? Dr. Alok A. Khorana: Yeah, that's a great question. So, to kind of summarize a couple of these things you talked about. So, one is we looked at these genomic alterations, and, yes, FGFR2 fusion was much more prevalent. It's close to 16% of young onset patients, as opposed to roughly 6% of average onset patients. So almost a threefold increase in FGFR fusion. And because there's so many drugs that are targeting FGFR fusion, and because the population included a period of time when these drugs had already been approved, we think some of the benefit or the improvement in median survival associated with being younger is likely driven by having more FGFR fusion and therefore having more drugs available to treat FGFR fusion related tract cancer with corresponding increase and increase in survival. And that was part of it. There was one other alteration, NIPBL fusion, that's been sort of known to be associated with a certain subtype of cholangiocarcinoma, but it doesn't really have a drug that targets it, so it's not sort of very useful from a clinical perspective.   The other two things you talked about, so transcriptome and immuno oncology markers, we found a couple different results on this. So one is that we found in younger people, angiogenesis was enriched, and why this is so we don't quite have a good answer for that. The other was inflammatory responses. So there's a couple of gamma interferon pathways and a couple other types of pathways that you can sort of do pathway analysis, and we found that those were enriched in the older patients or the average onset patients. But the benefit for immunotherapy was similar across the two groups. So even though we saw these differences in signaling in terms of which pathways are upregulated or downregulated, it didn't seem to translate into the current generation of immune checkpoint inhibitors that we're using in terms of benefit for patients. But we did see those differences.  Dr. Rafeh Naqash: I completely agree, Doctor Khorana. As you mentioned, that one size fits all approach does not necessarily work towards a better, optimal, personalized treatment stratification. So, as we do more and more sequencing and testing for individuals, whether it's early onset cancers or later onset cancers, figuring out what is enriched and which subtype, I think, makes the most sense.   Now, going to the FGFR2 story, as you and most listeners probably already know, FGFR is an approved target, and there are a band of FGFR inhibitors, and there's some interest towards developing specific FGFR2, 3 fusion inhibitors. What has your experience with FGFR inhibitors in the clinic been so far? And what are you personally excited about from an FGFR standpoint, in the drug development space for GI cancers?  Dr. Alok A. Khorana: Yeah, I think the whole FGFR fusion story sort of actually deserves more excitement than it's gotten, and it may be because, as I mentioned earlier, biliary tract cancers are a relatively low volume type of cancer. But the results that we are seeing in the clinic are very impressive. And the results that we are anticipating, based on some ongoing phase two and phase three trials, appear to be even more impressive for the very specific inhibitors that are about to hopefully come out soon.   Also, the possibility of using successive lines of FGFR inhibitors - if one fails, you try a second one; if the second one fails, you try a third one because the mechanisms are subtly different - I think it will take a little while to figure out the exact sequencing and also the sort of the rates of response in people who might previously have been exposed to an FGFR inhibitor. So that data may not be readily available, because right now most patients are going in for longer trials. But having that type of possibility, I think, kind of reminds me of the excitement around CML back when imatinib suddenly became not the only drug and a bunch of other drugs came out, and it's kind of like that. I think again, it's not a very common cancer, but it's really wonderful to see so many options and more options along the way for our patients. Dr. Rafeh Naqash: Thank you. Now, going to your personal story, which is the second part of this conversation, which I think personally, for me, is always very exciting when I try to ask people about their personal journeys. For the sake of the listeners, I can say that when I was a trainee, I used to hear about Dr. Khorana's course, I always thought that Dr. Alok Khorana was a hematologist. My friends corrected me a few years back and said that you're a GI oncologist. Can you tell us about your love for GI oncology and the intersection with hematology thrombosis, which you have had a successful career in also? Can you explain how that came about a little bit? Dr. Alok A. Khorana: Yeah, sure. So it is a common, I guess I shouldn't say misperception, but it's certainly a common perception that I'm a hematologist. But I'll sort of state for the record that I never boarded in hematology. I did do a combined hem-onc fellowship, but only boarded in oncology. So I'm actually not even boarded in hematology. My interest in thrombosis came about- it's one of those things that sort of happen when you're starting out in your career, and things align together in ways that you don't sort of fully understand at the time. And then suddenly, 10 years later, you have sort of a career in this.   But it actually came about because of the intersection of, at the time, angiogenesis and coagulation. And this is the late ‘90s, early two ‘00s, there was a lot of buzz around the fact that many of the factors that are important for coagulation are also pro angiogenic and many factors that are coagulation inhibitors. These are naturally occurring molecules in your body, and can be anticoagulant and anti angiogenic. A great example of this is tissue factor, which is, as you'll remember from the coagulation pathways, the number one molecule that starts off the whole process. But less widely appreciated is the fact that nearly every malignancy expresses tissue factor on its cell surface. This includes breast cancer, it includes leukemia cells, it includes pancreatic cancer. In some cancers, like pancreatic cancer, we've even shown that you can detect it in the blood circulation. And so for me, as a GI oncologist who was seeing a lot of patients get blood clots, it was particularly fascinating to sort of see this intersection and try and understand what is this interaction between the coagulation and angiogenic cascades that's so vital for cancers. Why is coagulation always upregulated in cancer patients? Not all of them get blood clots, but subclinical activation of coagulation always exists. So I would say I was fascinated by it as an intellectual question and really approached it from an oncology perspective and not a hematology perspective.   But then as I got deeper into it, I realized not everybody's getting blood clots, and how can I better predict which patients will get blood clots. And so I had both a hematology mentor, Charlie Francis, and an oncology mentor, Gary Lyman. And using sort of both their expertise, I drafted a K23 career development award specifically to identify predictors of blood clots in cancer patients. And that's the multivariate model that later became known as the Khorana Score. So again, I approach it from an oncology perspective, not a hematology perspective, but really a fascinating and still, I would say an understudied subject is why are cancer patients having so many clotting problems? And what does it say about the way cancer develops biologically that requires activation of the coagulation system across all of these different cancers? And I think we still don't fully understand the breadth of that. Dr. Rafeh Naqash: Very intriguing how you connected two and two and made it a unique success story. And I completely agree with you on the tissue factor. Now there's ADCs antibody drug conjugates that target tissue factor, both a prude as well as upcoming.   Now, the second part of my question is on your personal journey, and I know you've talked about it on social media previously, at least I've seen it on social media, about your interactions with your uncle, Dr. Har Gobind Khorana, who was a Nobel Prize winner in medicine and physiology for his work on DNA. Could you tell us about how that perhaps shaped some of your personal journey and then how you continued, and then also some personal advice for junior faculty trainees as they proceed towards a successful career of their own? Dr. Alok A. Khorana: Yeah, thank you for bringing that up. So very briefly, this is about my uncle. He's actually my great uncle. So he's my grandfather's youngest brother. And I grew up in India in the ‘70s and ‘80s, and at the time, I ran away from this association as fast as I could, because growing up in India in the 70s and ‘80s, it was a socialist economy. There wasn't a lot going on. There was certainly none of the IT industry and all of everything that you see right now. And so there were very few icons, and my great uncle was definitely one of those few icons. As soon as you mentioned your last name, that would sort of be the first question people would ask. But he did serve as a role model, I think, both to my father, who was also a physician scientist and a professor of medicine, and then to myself in sort of making me realize, one, that you can't really separate medicine from science. I think those are really integrated, and we want to ask questions and answer questions in a scientific manner. He chose to do it in a basic science world. My father did it in a clinical science world, and I have done it in a clinical and a translational science world. Again, sort of using science as the underpinning for sort of understanding diseases, I think, is key. And so that was certainly a massive inspiration to me.  And then after I immigrated to the US in the late ‘90s, I met him on a regular basis. He was certainly very inspirational in his successes, and I realized the breadth of what he had done, which I did not realize in my youth growing up. But this is a person who came to the US. This was before Asian immigration was even legal. So he got here and they had to pass a special bill in Congress to let him be a citizen that was based on the sort of work that he had done in Canada and in the UK before he came here. And then he sets up shop in the University of Wisconsin in Madison and hires tons of these postdocs and essentially converted his lab into this massive factory, trying to figure out the genetic code. Really just the type of dedication that that needs and the amount of work that that needs and the ability to do that in a setting far removed from where he grew up, I think it's just really quite mind boggling.  And then he didn't stop there. He got the Nobel for that, but I have these letters that he wrote after he got the Nobel Prize, and he was just completely obsessed with the possibility that getting the Nobel would make him sort of lose his mojo and he wouldn't be as focused on the next aspects of science. And he was just really dedicated to synthesizing DNA in the lab, so creating artificial DNA, which he ended up doing. And the offshoot of that work, so not just the genetic code, but PCR essentially was developed by his lab before it became sort of what we now know as PCR. And then ditches all of that in the ‘80s and ‘90s and moves to understanding the retina and just focuses on retinal disorders. And then signal transduction, essentially trying to figure out when a single photon of light hits your eye, what happens biologically. It's a completely different field. And just took that on and spent the next 20,30 years of his life doing that. So the ability to sort of change fields, I thought that was very inspirational as well, that you don't have to just stick to one question. You can get into one question, answer it as much as possible, and then find something else that's really interesting to you and that really grabs your attention, and then stick with that for the next couple of decades. So lots to learn there. Dr. Rafeh Naqash: Thank you. Thank you. And then, based on some of your personal lessons, what's your advice for junior faculty and trainees as you've progressed in your career?  Dr. Alok A. Khorana: I think, number one, and I can't emphasize this enough, and sometimes it actually causes a little bit of anxiety, but it is finding the right mentor. And for me, certainly that was key, because my mentor, who was Charlie Francis, was not an oncologist who was a hematologist, but was like me, sort of supported this idea of trying to understand, hey, why does coagulation interact with cancer? And so he approached it from a hematology perspective, I approached it from a cancer perspective, but he sort of gave me the freedom to ask those questions in his lab and then later on in the clinical setting and clinical translational setting, and then got me access to other people who are experts in the field and introducing you and then getting you on committees and making sure you sort of get into clinical trials and so on. And so having a mentor who sort of supports you but doesn't stifle you, and that's really key because you don't want to just ask the question that the mentor is interested in. And as a mentor now, I don't want to have my mentee ask the question that I'm interested in, but also a question that the mentee is interested in. And so there's a little bit of a chemistry there that's not always replicable, and it can go wrong in sort of five different ways, but when it goes right, it's really vital. And I mentioned it causes anxiety because, of course, not every day is great with your mentor or with your mentee, but over a period of time, has this person done sort of their best to get your career off to a start? And have you served that mentor well by doing the things that are– there's responsibilities on both sides, on both on the mentor and on the mentee. And if you can find that relationship where there's a little bit of chemistry there and both of you are effectively discharging both your responsibilities and satisfying your intellectual curiosity, I think that can't be beat, honestly. To me, sort of number one is that and everything else follows from that. So, the networking, making sure your time is sort of allocated appropriately, fighting with sort of the higher ups to make sure that you're not having to do too much, things that are sort of away from your research interests, all of that sort of flows from having the right person. Dr. Rafeh Naqash: Couldn't agree with you more, Dr. Khorana, thank you so much. It was an absolute pleasure. Thank you for sharing with us the science, the personal as well as the professional journey that you had. And hopefully, when you have the next Khorana Score, Khorana score 2.0, JCO Precision Oncology will become the home for that paper and we'll try to have you again maybe in the near future.  Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. Thank you so much.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Disclosures: Dr. Khorana  - Honoraria Company: Pfizer, Bayer,  Anthos, Sanofi, BMS, WebMD/MedscapeConsulting or Advisory Role Company: Janssen, Bayer, Anthos, Pfizer, Sanofi, BMS Research Funding Company: Anthos, Bristol-Myers,  Squibb Travel, Accommodations, Expenses Company: Janssen, Bayer, Bristol-Myers Squibb 

You can text us here with any comments, questions, or thoughts!We're thrilled to bring you an enlightening conversation with Kemi and Deepika Slawek. Dr. Slawek is an Associate Professor of Medicine at Montefiore Health Systems and Albert Einstein College of Medicine in Bronx, NY in the Division of General Internal Medicine. She is board certified in Infectious Diseases, Addiction Medicine, and Internal Medicine and is the Co-Director of the Montefiore Medical Cannabis Program. Dr. Slawek studies how to reduce morbidity and mortality in people with HIV (PWH) and people who use drugs (PWUD) using a harm reduction framework. She aims to study solutions for PWH and PWUD informed by her clinical experiences and patient's experiences. Dr. Slawek is the recipient of a K23 award from the National Institute on Drug Abuse to test how different formulations of medical cannabis effect neuropathic pain and inflammation in PLWH in an innovative quasi-experimental study. She is leading groundbreaking foundation-funded research to determine whether medical cannabis is effective in reducing opioid analgesic use in people with pain and is an alumnus of our Get That Grant® coaching program! In this episode, Dr. Slawek shares her passion for HIV research, the social justice aspects of her work, the transformative power of coaching and: The value of carving out time for self-reflection and understanding the "why" behind your actions. How stopping to evaluate your work can be challenging but ultimately leads to more effective and meaningful use of your time. The importance of aligning your daily tasks with your broader values and goals. How regularly taking the time to assess your work and its impact can keep you grounded and prevent burnout, especially when the world feels overwhelming. Loved this convo? Please go find Dr. Slawek on Twitter/X and LinkedIn and show her some love!  And if you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations.  REMINDER: Your Unapologetic Career Podcast now releases episode every other week! Can't wait that long? Be sure you are signed up for our newsletter (above) where there are NEW issues every month! 

Dr. Panigrahy is board certified in both Pediatric Radiology and Neuroradiology. He is a Professor of Radiology, Radiologist-in-Chief at Children's Hospital of Pittsburgh and Vice Chair of Clinical and Translational Imaging Research at UPMC. He has been continuously funded by the NIH since 2009 including both a K23 and current multi-center Ro1. He also has active funding from the Department of Defense, Society for Pediatric Radiology and private foundations. Dr. Panigrahy's research focuses on applying advanced MR techniques to the study of fetal/neonatal/pediatric brain development and injury in those diagnosed with congenital heart disease and its impact on neuro-developmental across the lifespan.

Studies show that transgender and nonbinary people are three to six times more likely to have autism than their cisgender peers. Researchers are still trying to better understand the connection. This week In the Den, Jen visits with occupational therapist Dr. Anne Kirby and Frank Vales, a trans and autistic student, about the intersection of the autism spectrum and gender diversity. Special Guest: Dr. Anne KirbyAnne V. Kirby, PhD, OTR/L, is an associate professor in the Department of Occupational and Recreational Therapies at the University of Utah, with an adjunct appointment in the Department of Psychiatry. She received her BS and MS degrees from the University of New Hampshire, and then practiced as an occupational therapist in multiple settings in Washington, DC. She received her PhD in Occupational Science from the University of North Carolina at Chapel Hill in 2015, before becoming a faculty member at the University of Utah. Her research expertise is in sensory processing, the transition to adulthood, and suicide risk and prevention for the autistic community. She is currently leading a K23 award from NIMH using community based participatory research for suicide prevention, in partnership with the Academic Autism Spectrum Partnership in Research and Education (AASPIRE). She serves as a Consultant on the University of Pittsburgh ACE grant.Special Guest: Frank ValesFrank Vales (he/him) is a 20-year-old student and artist born and raised in Salt Lake City, Utah. He is studying communication and writing with plans to go into the field of applied linguistics. He is autistic, disabled, and Queer, and is passionate about advocacy and community engagement. He has extensive public speaking experience on the topics of LGBTQ+ youth, mental health, autism acceptance, and suicide prevention. He is particularly interested in the intersection of Queer, neurodivergent, and disabled experiences and identities. In his spare time, he enjoys taking care of his unusual pets, including snakes and exotic cockroaches, and studying Irish Gaelic.  Links from the show: https://aaspire.org/projects/mental-health/suicidality/https://www.liebertpub.com/doi/10.1089/lgbt.2018.0252https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415151/https://pubmed.ncbi.nlm.nih.gov/30140984/https://www.nature.com/articles/s41467-020-17794-1https://faculty.utah.edu/u6002168-ANNE_V._KIRBY/research/index.hmhttps://www.spectrumnews.org/news/largest-study-to-date-confirms-overlap-between-autism-and-gender-diversity/Join Mama Dragons today at: www.mamadragons.org In the Den is made possible by generous donors likeConnect with Mama Dragons:WebsiteInstagramFacebookDonate to this podcast

In under a year, Kali Alexander has become one of the most recognized persona's in the ServiceNow world.  In that time she's started the popular #100DaysOfServiceNow podcast as well has a speaking session at K23.We go deep to find out what her secret is!Very special thanks to our sponsor, Clear Skye the optimized identity governance & security solution built natively on ServiceNow.ABOUT USCory and Robert are vendor agnostic freelance ServiceNow architects.Cory is the founder of TekVoyant.Robert is the founder of The Duke Digital MediaSponsor Us!

With this episode we kick off our set of interviews with some of our brightest and most innovative partners at Knowledge 23. For the first episode, Spencer Beemiller, welcomed Edua Dickerson, VP of ESG & Finance Strategy at ServiceNow to talk through some of the biggest takeaways of our time at K23 and more. See omnystudio.com/listener for privacy information.

Welcome to the Aphasia Access Conversations Podcast. I'm Jerry Hoepner. I'm a professor at the University of Wisconsin – Eau Claire and co-facilitator of the Chippewa Valley Aphasia Camp, Blugold Brain Injury Group, Mayo Brain Injury Group, and Thursday Night Poets.  I'm also a member of the Aphasia Access Podcast Working Group. Aphasia Access strives to provide members with information, inspiration, and ideas that support their aphasia care through a variety of educational materials and resources. I'm today's host for an episode that will feature Dr. Alyssa Lanzi. In this episode, we'll be discussing Dr. Lanzi's research on mild cognitive impairment and the role of the LPAA approach in serving individuals with mild cognitive impairment and dementia. Biosketch: Alyssa M. Lanzi, Ph.D., CCC-SLP, is a speech-language pathologist and Research Assistant Professor in the Department of Communication Sciences and Disorders at the University of Delaware. She is an executive committee member of the Delaware Center for Cognitive Aging Research at the University of Delaware. Dr. Lanzi is the PI of a K23 award from the National Institute on Aging to investigate the effects of an intervention designed to improve the independence of older adults with mild cognitive impairment from probable Alzheimer's disease. She is also MPI of awards that develop, test and disseminate a large-scale online database to study the language and cognitive skills of older adults to help develop cost-effective biomarkers to identify adults at risk for dementia from Alzheimer's disease. Dr. Lanzi's research broadly focuses on investigating person-centered assessment and treatment approaches for individuals with mild cognitive impairment and dementia and prioritizes the implementation and dissemination of evidence-based practice to practicing health professionals.  Take aways: The LPAA fits interventions for mild cognitive impairment too. We need to focus on training the next generation to understand the applications of LPAA to other disorders and contexts. You don't always need a standardized test, you can use goal attainment scales to measure anything. We need to be prepared to counsel individuals with mild cognitive impairment, as we are often the discipline having those conversations. When we intervene with individuals with mild cognitive impairment early, we can involve them as collaborators. There is a continuum of counseling needs that changes over time. See Alyssa's counseling plus paper in SIG 2 Perspectives.   Interview Transcript: Jerry Hoepner: Hi Alyssa. Good to see you. Alyssa Lanzi: Hi, good to see you. I'm happy to have a conversation with you today. Jerry Hoepner: Likewise, I'm looking forward to this conversation. It's kind of tradition that at the beginning of podcast we talk a little bit about your journey in your path to the life participation approach. So, I'm hoping that you can share a little bit about why an LPAA approach is so crucial to your research and clinical interactions. Alyssa Lanzi: Yeah, Absolutely. Well, thanks for having me, and I'm excited to kind of give a glimpse into how we can start to think about the LPAA approach outside of aphasia, because I think I'm a little bit unique in that way. And I am clinically trained as a speech language pathologist, and I was fortunate that most of my master's training was in a really strong university-based life participation approach model for aphasia. So, I had a large amount of experience working with Dr. Sarah Wallace and Katerina Staltari, and really thinking about group-based approaches for aphasia care. And I really fell in love with the functional nature of that model and with my master's thesis really tried to think about, well, how can we do this with individuals at risk for dementia with thinking about group-based approaches and functional care. And then I went on to get my PhD at the University of South Florida with Michelle Bourgeois. With a really strong research focus on functional approaches for mild cognitive impairment and dementia but also had the opportunity to work clinically the entire time during my PhD at voices of hope for aphasia under Jackie Hinckley, really learning about the life participation approach for aphasia. So, I feel super fortunate in that I have a lot of clinical work and exposure with the life participation approach that really has driven my research. Although I don't clinically practice with the life participation approach anymore, it really is a key foundation and a key kind of framework to how I have conducted all of my research and run the lab at the University of Delaware, which I'm currently a research assistant professor at right now. Jerry Hoepner: Excellent. Yeah. And thanks for sharing that, I really believe there is not a lot of transferability and generalizability of the LPAA in the approach being someone who has one world or one foot in the traumatic brain injury world, and another foot in the aphasia world. There's definitely some strong carryover across those contexts, and I think members of aphasia access are really interested in thinking about how that extends into those contexts. So, I really appreciate that. And like I said before, you have quite the pedigree in terms of experiences with very life participation approach minded academics, and having some of those clinical experiences, is really just so crucial for those, you know, when you step into the research world that you're doing something that really applies. So, I know you already talked about Sarah Wallace and Dr. Satari and Dr. Bourgeois and Jackie Hinckley. But are there other people along that journey that have kind of shaped the way that you think about LPAA applications to aphasia but beyond obviously? Alyssa Lanzi: yeah, I think you know, really the names that you mentioned were kind of the key mentors in the process. However, individuals like Roberta Elman, and really her approach to kind of book and learning and reintegration was structured. But flexible activities are really kind of key to my thinking, and also, as you know, an early career researcher as well. Folks like yourself and Tom and Katie really show how we can also train students in this approach as well, which is kind of being key to figuring out how I really run this lab that's based in life participation. That's not only my line of research, but also supporting the next generation. I feel fortunate in that I have mentors that really have integrated a life participation approach in many different settings from big R1 universities to smaller, R2, and R3 universities to clinical practice settings to nonprofits. And I think I've taken pieces of all of those to really support my research and teaching pedagogy, and really life participation in that way, and without aphasia access, I wouldn't have had access to those leaders and mentors in the field like yourself, and it really has given me an opportunity to have conversations with these folks, and every single conversation has really impacted and influenced my work thus far. Jerry Hoepner: I think that tends to be a really common reflection on aphasia access that everyone is so accessible. So, the name really says it, and willing to have those conversations. And certainly, that supports us in all of those avenues, research, clinic, well and academic in terms of teaching as well so completely agree with that. Alyssa Lanzi: I think that's what's a beautiful thing about aphasia access and the life participation approach is that it's not just research, either. Right? It's research, it's clinical, it's teaching, it's mentoring, it's service. And I think we will probably talk about in a little bit. But in all of my work that's really what I try to think about, I don't just try to think about, you know, research, I try to think about well, how can I study this so it can actually be implemented in clinical practice? And then how can I also teach the next generation using this approach in that way? And I think that framework, although we often think of life participation as like a clinical approach. In some ways it's really this entire framework to all those kind of core components that are necessary in terms of teaching, research, clinical care and service. Jerry Hoepner: I really love the way that you describe that, because I don't know that that's been done really clearly before. But there is a thread running through all of those pieces, and it kind of speaks to your experience with Jackie Hinckley in terms of thinking about that implementation piece, and how we make sure what we're doing matters, and is the right stuff in the first place. And obviously teaching is near and dear to my heart, and being able to frame that in a way that students understand, but also feel like it's not something that's high in the sky that you know only a few people do, but that's accessible and usable by everyone, and even for my students. I mean, I know that a lot of my students will end up in a school setting, and I know that these foundational principles of LPAA still have relevance to them. So, I say, you know, regardless of where you're going. This content matters, and it should shape the way that you think conduct LPAA work. Alyssa Lanzi: Yeah, you don't have to be at a center to conduct LPAA work, you don't have to be with people with aphasia to conduct LPAA work, and that's the cool part of it. And having these conversations is an opportunity to kind of brainstorm with one another of, well how do we take you know, from the traditional mold, how do we kind of break that and really think of it as threads that can be kind of interwoven into all these elements that are core components of our discipline in a lot of ways. Jerry Hoepner: Agreed. Maybe that's a new task for aphasia access worker to kind of map all of those pieces, because I do think not. Maybe individuals have those pieces, but it hasn't been all put together. So, I appreciate that overview. Alyssa Lanzi: And yeah, hopefully. Jerry Hoepner: well. I've been having fun re-reading and refreshing myself on your work on. I used a lot of it within my teaching so. But it's always fun to see when you read something again that you pick up something that you just didn't even like process before or you don't remember you process it, maybe. But clearly, I mean, there's this thread going through all of it about person-centered strength-based care right at the heart of all of that. It really one of the things that stood out to me the last couple of days as I've been meeting is that emphasis on fostering choice and collaboration along the way in every single step with the with the individual, with mild cognitive impairment or dementia, with their family members. And I think that's really crucial. I mean whether you're kind of choosing an external memory aid, or script, or whatever is best right. Can you talk about how you facilitate those choices? Maybe a little bit about the kinds of tools that you use on one end, but also a little bit about how you just foster a mindset of that collaborative decision making, because, you know, sometimes people can just want to defer to you and say you tell me so. I'm interested in your thoughts on both of those pieces. Alyssa Lanzi: Yeah, Absolutely. Well, thanks for the flattering words, and I'm happy. You picked out the core elements there, because I think those are really kind of the key words of a lot of the work that I try to do, and starting really with person or family centered, in that way, and it's tricky. I think a lot of people say that their work is person centered, and we can always argue. What do you mean by that? And how do you ensure that, same with functional right? But something I try to teach people, and my students are just because it's related to something practical doesn't necessarily mean it's a functional approach, either, you know, so really kind of parsing out by what we mean by that. But in particular, with working with folks with mild cognitive impairment and dementia, the goal is to really support their independence for as long as possible, and then to support their quality of life right? And a lot of times when thinking about people with chronic aphasia, it's very similar in that way, right? And that, you know, kind of gotten to a point. Not that improvements can no longer been made, but the shift is really about like, well how can you live the best life as possible? Right? How can we get you participating in as many things as possible, and that's the same mindset when we're working with people with mild cognitive impairment in particular. So, when I'm trying to design the treatment approaches that I'm testing with my clinical trials. Really, the whole framework is, how can we make something structured and standardized but flexible to that individual's needs. So, I think it starts from a treatment level, figuring out what are the active ingredients? What are the things that can't be changed, what are the core elements that can't be changed. And then, once we figure that out, then the meat of the sandwich, you know the meat of the treatment can be customizable to that individual right. And a lot of this work really comes from McKay Solberg, and views of cognitive rehab as well. But I think, when we think about person centered, we need to think about what are the core elements of this evidence-based approach? What are the active ingredients? And then what are the things that can change in between right? And when we're talking about external memory aids, it's not enough just to give somebody a calendar right. We're not seeing that individuals actually continue to use this calendar later on. And I would argue that's because of 2 reasons, one because we didn't systematically train them, and the use of it and 2 is because we didn't include them in the process from the start to the finish. And you are asking about what kind of tools and what things can be helpful. And in terms of thinking about goal development tools, a lot of times we can lean on our colleagues and occupational therapy and use a lot of the models that they have for goal development. So, they have the COPM which I'm probably going to butcher the name, but it's the Canadian Occupational Performance Measure, I believe it is, and that can be a really great tool to have a structured approach to goal setting. Same with goal attainment scaling, and incorporating some motivational interviewing techniques on top of it. But the key is that you have some type of structure, some type of evidence-based approach, on top of the conversation that you're having right, just asking somebody their interests is important, but we need to think about what's the best thing for our buck, since we have such limited time with them. So those 2 tools, in terms of goal setting have been really helpful for me, paired with using patient reported outcome measures and kind of figuring out how to use that as an initial conversation, and then paired with some further probing of tell me more about these items. Tell me more about the issues that you're facing. And then what I think is tricky, and where I relate most to my life participation colleagues are, what are the outcome tools, or what are the treatment planning tools that we can use to design these participation approaches. And it's hard because most of the outcome tools that we have are developed for looking at impairment-based improvements, right? So very decontextualized type tasks and that's really tricky. If the treatments that we're doing are all meant to be functional and person centered and improved participation. But we're not looking at necessarily improvements in worthless learning, or serial sevens or things like that. So, I couldn't figure out any tools. So, part of my dissertation work was designing a measure that was really aimed to help drive treatment planning. And then look at if there's gains an actual participation, so that tools called the functional external memory aid tool, and my lab in the last year or so have tried to do a lot of work, and coming up with free resources to train students, clinicians, and researchers, and how to use this tool to drive treatment planning because it's a little bit of a different way than we think of how to use assessment tools. Traditionally we think of assessment tools to tell us is that that person has an impairment or not and this is not designed in that way. It's really designed to tell you how to design your treatment, and a functional meaningful in person-centered way. I don't have great answers of what the tools are, but I think collaborating with clinicians and collaborating with evidence-based researchers really helps us to try to fill that gap in some ways. Jerry Hoepner: Yeah, and I think you got at part of it when you talked about goal attainment scales that you could make that a measure of any goal that the person identifies themselves. You don't necessarily have to try to fit a tool around that you can just measure what they hope to change right, or what they hope to sustain in terms of function. So, I think that's really good and really helpful. Just want to kind of circle back to a couple of things you talked about active ingredients, and how to really recognize what those active ingredients are, what the cores are, and what is content that you can do without, so to speak, made me think of some of the recent work in RTSS from the standpoint of really mapping that out. But I think that principle of my own is really important. Just to be able to say what is at the core? What do I always need to do? And what is kind of supportive of that, and can be individualized? So that's really helpful. Alyssa Lanzi: That shouldn't be on the clinician either right? If you're a clinician listening to this like that shouldn't be on you. This is on the researchers to consider from the beginning, and this should be really clearly outlined in this plan. And it is somewhat hard to figure out what some of these analyses like what are the active ingredients? But that's really, if you go to a talk, if you're a clinician on this call like that's what you should be asking, when you go to these talks like, what are the active ingredients? What do you think is really evident of what's making the change? It's not on you to decide. It's really on researchers to be thinking about this from the beginning, and not for you to try to figure out by any means. Jerry Hoepner: Yeah, I think that's a really some really sound advice, because finding out what those active ingredients are that's really crucial, and I think there's times, and I won't say who, but I reached out to a researcher once to do some work related to their work, and I said, “So do you have some place where you have more specific information about what exactly you did?” And they said “it's all in the paper” and I was kinda like no, it's not all in the paper, and I think we're getting better at that, providing that information, at least to the best of our knowledge, what those active ingredients are. And you know this is on the researcher to provide that, and then to allow that clinician to be able to work within that framework. So, I'm really glad that you said that. I also wanted to highlight the fact that you talked about your measure, and I think the acronym is FEAT right? Alyssa Lanzi: FEMAT, yep, close. Jerry Hoepner: Sorry. Missed it. I missed one letter, but we'll make sure that that is in the list of resources at the end as well, so that people know how they can access that information, and you mentioned that you're trying to make as much freely available as possible. So I think that's really helpful for our listeners to know where to find that information. Alyssa Lanzi: Yeah, the tool can be downloaded completely for free. And there's educational and training resources for free on there as well as we just publish an open access manuscript, describing with case examples of how to use it as well, because if we as researchers want clinicians to use our work. Constantly, we're hearing the biggest barriers pay walls and everything else so really trying to make this as accessible as possible, so that individuals can actually use it in their practice. Jerry Hoepner: Well, that's really excellent. I really appreciate it, so I'll double check with you at the end, and we'll make sure we have all of that information there for the for the listeners to follow up on that. So, getting into the connection and the differences between someone with aphasia and someone with a mild cognitive impairment. There's a lot of overlap and most communication supports. And as I was reading your work, I was like overlap, overlap, overlap. But there's also some ground that isn't overlapping individuals with aphasia, particularly when you get to the cognitive kinds of constructs, and so forth. So, in terms of supporting someone with MCI or dementia. What are the key distinctions that you have in your mind about how to approach that. So, distinguishing them from maybe what you would use for a language assessment, or language support excuse me, for someone with aphasia Alyssa Lanzi: I think the good thing is, there's many more similarities than differences. Right? We have this strength-based approach, this idea of participation, reintegration, isolation, depression. These are all major psychosocial factors that we know are associated with both populations and also acute. You know older adults are highest at risk. Right? We're seeing similar populations in some ways as well, so that strength-based participation-based reintegration, type approaches are all very similar. You know the key distinction or the key differences, I should say, is unlike people with a stroke, there wasn't an event that caused the impairments right, and that instead, we need measures that are really sensitive to early declines right? So, it's not like these individuals had a stroke or a brain injury, and immediately referred to speech, language, pathology. That's a very different pipeline to referral in that way. So, speech, language, pathologists need to do a much better job of advocating for our role early on where I don't think we have to do as much of that advocacy with people with aphasia now. Yes, all the aphasia folks don't come at me either because I know there's plenty of advocacy work that we need to do as well, but it it's a little bit different right, and that once aphasia is diagnosed, it's pretty clear that SLPs are the one to go to for the most part. For individuals with mild, cognitive impairment it's a bit different. So, we need to do a lot of advocacy work, and many of our tools, unfortunately, are not sensitive enough to these early declines. What's exciting is that language is actually showing as a pretty promising tool, a pretty sensitive metric. So, hopefully in the next, you know, 5 to 10 years we're starting to actually definitely be involved because we're noticing language changes or sensitive to these early declines, but so one is the early process, and the referral process is quite different. The other key difference in my mind is the preparation for the future and that individuals of mild cognitive impairment are at a very high risk for developing dementia due to Alzheimer's disease and in my work I am talking about mostly these clinical syndrome due to Alzheimer's disease is usually the bulk of my work. But for individuals with mild cognitive impairment. We really want to set them up with these tools, so that we can develop really strong habits and routines now and really rely on the strength of procedural memory, so that if they decline, they have these really good systems in place, and that's a very different mindset than people with aphasia. So, the mindset in that way is very different in our role in preparing for the future. So, I think the referrals is probably the big pipeline. How they get to you. The coping and the depression is all there. But viewed a bit differently. It's not, Oh, my God! My life has drastically changed instead it's, Oh, my God! What's gonna happen, you know, in 2 3 5 years. So, it's all those same constructs are there, but the rationale and the underpinnings are a bit different. Jerry Hoepner: I want to just go back to a couple of the points that you said again. When I'm thinking about that that early intervention or early work with someone with MCI, I'm always telling my students part of what you said that idea that we want to establish those routines and habits. But the other thing I always think about going back to our previous discussion is that's the opportunity for them to make as many decisions about their future as they possibly can, and do that planning for the future. I find that to be a really effective way from a counseling standpoint to get them involved in kind of planning their future, and also building that acceptance right like this is coming. What can I do now to kind of take ownership and to take control of that versus if I wait, then it's going to be someone else's decision. Alyssa Lanzi: Exactly. Exactly. We describe it. A lot of you want to be in the driver's seat and not the passenger seat. Jerry Hoepner: Yeah, great metaphor. And I just wanted to mention one other thing when you were talking about that the fact that language is a really sensitive measure. You believe for individuals with MCI and predictors of for their dementia. You know some great work with the dementia bank in terms of talking about collecting samples and interpreting those samples. So, I know I'm kind of putting you on the spot for this. But any thoughts about that might lead us in the future in terms of knowledge. Alyssa Lanzi: Yes, stay tuned. We more than likely have a pretty big grant coming our way, which is going to be exciting. But the current biomarker tools for detection, are costly and invasive. We're having MRI and imaging techniques which are costing, You know, so much money. Blood is becoming, you know, blood based biomarkers are at least a bit more cost effective. However, there's still quite still, quite invasive, and there's only a certain person who wants to come into a lab, you know, and do those types of things. So what we're hoping is that we can use language, and that people can provide us with language samples in the comfort of their own home, right and really reflective of these functional tools and paired with these other. You know data, this, this other data that we're collected, we can make this really kind of informed decision or inform diagnosis. So, hopefully, you know, we can get to the point where that is the case that people can kind of just answer some questions from the comfort of their own home and their smart home and their computer. And you know, on the back end we can analyze their language, and then, provide them with some information about what we're thinking in terms of diagnosis and things like that. The most exciting thing to me in my mind about language is that hopefully, we can get a sample of individuals to participate who are actually representative of those who have the disease and that with many of these imaging techniques, and with many of the blood-based biomarkers and these invasive techniques, there's only a certain type of person you know who wants to come to campus and do these things, and most of our large databases are really white, high SES folks who are just, not those who are at greatest risk for the disease. So, what I'm really hoping for with as really the area of language grows, thanks to a lot of the work that we're doing, and Carnegie Mellon are doing with Brian and Davida, and also Kim Mueller and her group at Wisconsin. Is that not only can we use it as a sensitive measure, but we can get people to participate because, hopefully, it reduces the common barriers to participation in research studies. So that's really kind of a focus of where we're going. And then, hopefully, with that information, we can better support those who are at greatest risk living with this disease. Jerry Hoepner: Right and it seems like there's kind of a secondary effect to once you have those answers. There's a lot more SLP's than there are, you know, other mechanisms for measuring those bio measures. So, if you know that contact, maybe we can contribute to that earlier detection as well, so that's fantastic. Alyssa Lanzi: Yeah, which is why we need more SLPs going in this space, and I love aphasia work. I'm an aphasia clinician at heart. But I hope we see after today and through many of my other colleagues that the world overlap so much. But we really need a lot of researchers in this space, because speech language pathologists have a lot that they can contribute, and could very soon be at the forefront of the of the diagnosis as well. So, any students on the call or clinicians wanting to go back. My labs and others are really recruiting, and we need more individuals who are interested in researching in this space. Jerry Hoepner: Yeah, that's great to share. And hopefully there are some students and professionals out there that are thinking about that so definitely need that. Well, I'm going to change gears just a little bit. You've talked a little bit about depression and other mental health issues a little bit, isolation that occurs not only with aphasia, but with mci and dementia. I think we're all starting to get a better idea of our roles as speech, language, pathologists, in terms of counseling individuals with aphasia, MCI, dementia, traumatic brain injuries, etc. In re-reading your 2021 paper about counseling, plus I was really struck by how you and your co-authors mapped out this continuum of counseling needs kind of makes me want to do the same for everything so in activities from the first symptoms and diagnosis to the end of life, and I'll refer our listeners to figure one because it's a really eloquent framework for, and timeline for those changes. Will you share a little bit about the development and kind of the purpose of that timeline figure. Alyssa Lanzi: Yeah, thank you for the kind words that was probably one of the hardest things I've ever done was writing that paper, but we knew it needed to be done for many different reasons, but really to paint the picture that SLPs have a key role from the start all the way to the finish with these folks, and that's really what that figure is trying to highlight is that we can provide both primary and supportive roles to our colleagues from prevention and education all the way through end of life. And fortunately, that figure has really resonated with a lot of people which has been really helpful and I've actually gotten a lot of feedback from clinicians who've been able to use it to advocate for their role in this working with this population and doing support groups and things like that. So that's really great, because that's the whole point of it. But what's unique about this paper is that I work on a very interdisciplinary team of neuropsychologists and geriatric psychiatrists. And it was really interesting to come at it with all 3 of our mindsets for kind of developing this, because everybody has a very different education in terms of these important psychosocial constructs. So a really big shout out to my colleagues, Matt Cohen and Jim Allison, who really also helped me push my mindset of thinking about counseling as much more than just a conversation, and really thinking about counseling, plus as we call it, in terms of everything else right, and that a conversation is only the start of it, and that education and management and advising and referrals, that's all, that's all the big piece of it. So, I think that's why we were able to really round out this figure is because we were coming at it from 3 different disciplines as well, and then being able to go back to okay Well, what's within the scope of practice, of speech, language, pathology. The other thing about this figure is you'll see that the x-axis, the way that we looked at over time was by residential status, not by necessarily MMSE score or MoCA score right, and that framework was very much from my background in life participation approach in thinking about okay, let's think about them on a continuum of like residential needs versus what is their cognitive status on like an impairment type measure. I encourage people to think that way when we think about working with older adults in particular with neurodegenerative conditions, and that not thinking about them as a numerical value in a stage on one type of those measures because I think it opens up our roles, and also shows how hopefully within that figure that you can see that the roles overlap. Right, there's some roles that we start from our first conversation that we're going to continue all the way through the end of life. The other really important thing to consider with the figure, is in our field we have a really strong understanding of like language milestones in pediatrics, right? But what we don't have a really good strong foundation is, is understanding what is typical aging right, and our role in supporting healthy aging as well. Just as we support language development in pediatrics. So that's a big piece of this figure and a big piece of the counseling article is that we have a major role like we do in language development in healthy aging development as well, and that we can do a lot to support healthy aging and prevention just like we do in language development of kids, and also like we do like with the FAST acronym for stroke or with concussion protocols and management, we just haven't, yet kind of adapted that approach to aging, and that's what hopefully this figure gets us to start to think and talk about as well. Jerry Hoepner: I think it definitely does. And I really like that analogy or metaphor comparison between the developmental milestones, because I was thinking that as I was looking at the figure, this is really similar. It kind of reminds me of, like the norms we looked at when we were in child phono or child language development laid out in the same kind of framework. So, I think that's something that is really comprehendible by the average SLP, and I think that's helpful, and I and I love how you describe x-axis in terms of those descriptions rather than numbers, just so crucial to see the person from that lens rather than as simply those numbers. So. Alyssa Lanzi: Yeah, in addition to my LPAA colleagues, my early intervention birth to 3 colleagues, or who were the closest with in a lot of ways, I definitely the treatment approaches the in-home approaches. They're in the next group, I would say. That is pretty close to LPAA as well in some ways is early intervention. Birth of 3. Jerry Hoepner: Agreed. Yeah, that's it. Another really great point. The other thing I really liked about the terms and you mentioned this: I think part of this comes out of the interprofessional kind of nature of development. But when you look at them, sure some of them are, you know, you think. Oh, yeah, that's counseling still, but many of them you don't necessarily wait to. Oh, yeah, that's in my counseling tool belt, and I think it's important for people to recognize those things are a part of that counseling process, and that can make it a little bit more accessible. I mean, we know that from an education standpoint that people are intimidated by counseling, and they feel unprepared and inadequate to carry out those steps. So, I mean just being able to see that on paper and say, I can do these things, I know these things, I think, are a really valuable part of that framework as well. So. Alyssa Lanzi: And to make sure that when we are describing counseling to our students, we're describing that as well, right, because its such a daunting thing for our students and if we help them in the beginning set up education, it really breaks down some of the common barriers to providing counseling of its daunting and scary. But a support group is one really small element of counseling that's within our scope of practice and our scope of practice does define it really well. I just think that how we describe it in articles is way too specific, and we need to think about it much more broadly and through, like the journal that you're responsible for with teaching and language. And you know we're starting to develop these models which is really helpful as well. But I agree, I think we just need to step outside of our really kind of specific way of thinking about counseling, because once again, then, by having a more broad continuum viewpoint. It really shines through our role. And why we are such key players of the team. Jerry Hoepner: Yeah, agreed. I mean, we are always going to be the ones who are put in that moment, that counseling moment we have to be prepared and stepped into it so obviously. That's my bias. But I think we always are. Well, this has been a fantastic conversation, and I could go all afternoon, but want to keep this reasonable for our listeners too. So, I want to end on kind of a broad question, just in terms of what's your advice for SLPs and other disciplines, for that matter, in terms of working with individuals, with mild cognitive impairment and dementia, specific to the use of the external strategies and supports, but kind of weaving, counseling into those interactions? Alyssa Lanzi: Make sure we're really listening to our patients and our families and take that extra second to pause and really make sure they feel valued and heard because especially for these individuals, they're scared. They may not yet see consequences in their everyday life. So, we need to really have a lot of buy in, and good rapport with them from the beginning, because they can make key changes in their life that may actually delay the onset of dementia. But they need to have buy in from you, and they we need to really promote behavior change and to do that they need to feel, listened to and heard. So, take the extra second and make sure you're doing that. Then I think, make sure that we are providing evidence-based approaches around these strategies that we are teaching and the 3-step approach by Solberg and Mateer and the pie framework. All of these, you know, meta-cognitive strategy frameworks. It starts with education, and we need to make sure that our clients have a really big education of what even is the strategy? What are all the components of the different strategy? Why is it they are even using the strategy right? Don't, jump into training the strategy yet, really start with the education and use the teach back approach, and make sure that they can help you in that way and then make sure you also don't view your approach as linear, things are going to change right, and you're going to have to go back a step and go to education. But you know I think functional is key and important, but it doesn't mean that we take away the evidence based, either right. And it's really thinking about how to integrate both of those things, and being honest with yourself and your client if things aren't working, and you need to readjust as well. But if your patient feels valued and heard, then that's the first step, and we need to make sure that we're continuing that step all the way through to the end of the sessions. Jerry Hoepner: Absolutely agree. Well, again, it's been a fantastic conversation. So really, thank you so much on behalf of Aphasia Access for your time and your insights and hope to see you again soon. Alyssa Lanzi: Yes, thank you. Please feel free to reach out. And if you ever see myself or my Doc students, Anna or Faith, or my colleague, Mike Cohen, at a conference. Please say hi to us as well. We love talking about our work and brainstorming with others, especially in the LPAA world. Jerry Hoepner: Sounds terrific. Thank you, Alyssa. Alyssa Lanzi: Thank you. Jerry Hoepner: On behalf of Aphasia Access, thank you for listening to this episode of the Aphasia Access Conversations Podcast. For more information on Aphasia Access and to access our growing library of materials go to www.aphasiaaccess.org. If you have an idea for a future podcast series or topic, email us at info@aphasiaaccess.org. Thanks again for your ongoing support of Aphasia Access. Articles & Resources: Cohen, M. L., Harnish, S. M., Lanzi, A. M., Brello, J., Victorson, D., Kisala, P. A., ... & Tulsky, D. S. (2021). Adapting a Patient–Reported Outcome Bookmarking Task to be Accessible to Adults With Cognitive and Language Disorders. Journal of Speech, Language, and Hearing Research, 64(11), 4403-4412. Lanzi, A., Burshnic, V., & Bourgeois, M. S. (2017). Person-centered memory and communication strategies for adults with dementia. Topics in Language Disorders, 37(4), 361-374. Lanzi, A., Wallace, S. E., & Bourgeois, M. S. (2018, July). External memory aid preferences of individuals with mild memory impairments. In Seminars in Speech and Language (Vol. 39, No. 03, pp. 211-222). Thieme Medical Publishers. Lanzi, A. M., Saylor, A. K., Fromm, D., Liu, H., MacWhinney, B., & Cohen, M. L. (2023). DementiaBank: Theoretical Rationale, Protocol, and Illustrative Analyses. American Journal of Speech-Language Pathology, 32(2), 426-438. Lanzi, A. M., Ellison, J. M., & Cohen, M. L. (2021). The “counseling+” roles of the speech-language pathologist serving older adults with mild cognitive impairment and dementia from Alzheimer's disease. Perspectives of the ASHA special interest groups, 6(5), 987-1002. Links:  FEMAT Website  FEMAT Open Access Manuscript  Delaware Center for Cognitive Aging Research- Free Memory Screenings  Counseling+ Open Access Manuscript  DementiaBank Open Access Manuscript  DementiaBank- Free Discourse Protocol 

This episode features an interview with Dr. Alyssa Lanzi about her academic journey to become a Research Assistant Professor. During this conversation, Dr. Lanzi discusses her previous experience in a postdoctoral position where she applied for, and was awarded, her own K23 grant funding. We also discuss how she strategically chose her postdoc position and negotiated her responsibilities. Dr. Lanzi then shares how she transitioned into her Research Assistant Professor position at the same institution and describes what this role entails. This is a great listen for anyone interested in a postdoc position or research-intensive academic position in the field! You can connect with Dr. Lanzi on Twitter @AlyssaLanzi and learn more about her work at https://sites.udel.edu/recall-lab/. You can find the show notes and a transcript of the episode at aboutfromandwith.com.

Ya se encuentra en Girona la selección mexicana preparándose para el mundial con un par de juegos amistosos y en espera de confirmar quienes serán los 26 que vivan la experiencia de contender en Qatar 2022; La influencer Kenia Os, cuenta porque su disco K 23 enganchará a la gente; Los casos de influenza se adelantaron de forma agresiva en los Estados Unidos

Ya se encuentra en Girona la selección mexicana preparándose para el mundial con un par de juegos amistosos y en espera de confirmar quienes serán los 26 que vivan la experiencia de contender en Qatar 2022; La influencer Kenia Os, cuenta porque su disco K 23 enganchará a la gente; Los casos de influenza se adelantaron de forma agresiva en los Estados Unidos

Devilwalk joins HLTV Confirmed to talk through in detail the results of IEM Rio Major qualifiers, including the disasters of G2 and Astralis, k0nfig departing the team and telling his story, and the last dance of FalleN. ➡️ Follow us for updates: https://twitter.com/HLTVconfirmed

Dr. Kiara Alvarez is a child clinical psychologist, a researcher focused on mental health inequities in the field of youth suicide prevention and the wellbeing of Latinx and immigrant youth and their families. She is also an alumni of my Get That Grant coaching program and an ongoing amazing coaching client.Take a listen to hear some real behind the scenes of her coaching journey:- What her ‘unicorn' criteria were for finding a coach- Securing a K23 in a well-respected institution and something still being off- The coaching tool that finally helped her gain a unifying clarity on her career goals- Finding sanity and a different relationship to work in the midst of a pandemic with a 3-year old at home- How shifting to see grants as the tool, and not the goal, led her to do something she'd never done before with her R34 application- What it's really like to be in a radically authentic community with a shared processIf you loved this convo, please go find Kiara on Twitter (@kalvarezphd) and show her some love!

Was genau die Begriffe "Love-Scam" oder "Fake-Shop" mit unserem heutigen Thema "Cyberfraud" zu tun haben, erzählen euch in dieser Folge die Frankfurter Kollegen Markus und Michello von der Ermittlungsgruppe 5 des K23. Ihr wollt außerdem wissen, wann genau der Waren- oder auch Leistungsbetrug im Internet anfängt und wie man sich davor schützen kann? Dann seid ihr hier genau richtig. Nichts wie los und reinklicken!

1:35 - Трансферный блок 1:35 - Ence 10:10 - Fnatic и немного о шведском КС 15:35 - замены в Винстрайк и насколько тяжело говорить людям, что с ними расстаются и насколько тяжело слышать, что тебя кикают 22:13 - Rivalry в КС, привязанность к тэгам 28:12 - Spirit, Forze, K23 32:46 - Extremum и где им играть 37:55 - Мажор, РМР турниры (до объявления) и потенциальное возвращение лана 46:10 - Академии и юношеские составы 55:25 - Бласт, победа НаВи, провал Г2, первое выступление Ликвид с Фолленом Ваш фидбэк вы можете оставлять либо в комментариях под аудиозаписями, или же в телеграм-канале t.me/ezpzpodcast, или же напрямую мне в твиттер @pradiggg. Любая конструктивная критика будет нам полезна, чтобы развиваться, работать над собой и улучшать качество контента. Заранее спасибо! Также нас можно послушать на Google Podcasts, Apple Podcast или Яндекс музыке. Если Вам понравился наш подкаст, подпишитесь на нас и поставьте лайк. Так же, подписывайтесь на нас в твиттере и телеграме. Спасибо за внимание!

What does the research show in regard to how teens' social media use impacts mental health? How can parents support their teens in using social media in healthier ways? How can teens use social media in healthier ways? Jacqueline (Jackie) Nesi, PhD is an Assistant Professor at Brown University in the Department of Psychiatry and Human Behavior and a clinical psychologist answers these questions in this podcast about social media and adolescent mental health. Dr. Nesi's research examines the role of social media in adolescents' peer relationships and mental health, with a focus on depression and suicidal thoughts and behavior. Her work has been funded by the National Science Foundation (NSF) and the American Foundation for Suicide Prevention (AFSP), and she is currently funded by a K23 award from the National Institute of Mental Health (NIMH). She has published in numerous peer-reviewed journals, including Journal of Adolescent Health and Journal of the American Academy of Child and Adolescent Psychiatry, and her work has been featured in popular media outlets such as the Wall Street Journal and Teen Vogue. Dr. Nesi is passionate about understanding how and for whom social media use influences adolescents' mental health, so as to identify and intervene with youth most at risk. For useful information on this topic visit the following sites: Common Sense Media - https://www.commonsensemedia.org; Children and Screens - https://www.childrenandscreens.com/virtual-workshop-series/

Show #871   Good morning, good afternoon and good evening wherever you are in the world, welcome to EV News Daily for Wednesday 19th August 2020. It’s Martyn Lee here and I go through every EV story so you don't have to.   Thank you to MYEV.com for helping make this show, they’ve built the first marketplace specifically for Electric Vehicles. It’s a totally free marketplace that simplifies the buying and selling process, and help you learn about EVs along the way too.   LUCID SUV SPOTTED "Driving through Pescadero someone came across a Lucid shoot and took these pics. They blocked off the road with CHP for the Lucid Air & Lucid SUV. The pics aren’t that great - direct quote: "My iPhone 10 zoom isn’t clear enough to show how beautiful these Lucid cars are. I’d buy one now!" The shoot appears to be in preparation for the reveal? Here they are. With differences in outdoor lighting, shadows, background, and taken with an iPhone 10 zoom it's nearly impossible to see the true colors."   8 photos.   https://lucidowners.com/threads/here-they-are-lucid-air-suv-pics.39/   GENESIS EG80 ALL-ELECTRIC LUXURY SEDAN SPIED NEAR THE NURBURGRING "Genesis updated its flagship sedan earlier this year, etching the GV80 SUV's design onto the refreshed model. It debuted with two gas engines, and, outside the US, a diesel. However, new spy photos from near the Nurburgring show the luxury brand is developing another powertrain for the G80 – an all-electric one. " says Motor1: "There are zero details about the electric powertrain. We don't know how many motors it'll have, its range, or the battery pack's capacity. TheKoreanCarBlog.com reported last month that the eG80 would compete against cars like the Tesla Model S, Mercedes EQS, and others, and it'll arrive within two years. Genesis is also developing the ability to perform over-the-air firmware updates to the vehicle like Tesla does with its model, giving the eG80 the capability to change and improve a range of vehicle functions."   https://www.motor1.com/news/439662/genesis-g80-all-electric-spy-photos/   BOLLINGER DOUBLES STAFF AND MOVES TO MICHIGAN "Bollinger Motors has quickly made itself at home since moving to Michigan from New York. From a studio space to a headquarters in Ferndale, both in the Metro Detroit area, it has continued to develop and show off prototypes of its all electric B1 sport ute and B2 pickup truck. Its staff has grown considerably, and its looming product portfolio has grown, too (now including an electric chassis cab based on the B2 for commercial applications)." writes Autoblog: "The move comes as Bollinger plans to double its workforce to about 80 team members by the end of the year. The all-electric B1 and B2 are designed for serious off-roading. They feature a dual-motor powertrain that delivers 614 horsepower and 688 pound-feet of torque, have a payload of over 5,000 pounds, and a towing capacity of 7,500 pounds. An adjustable hydro-pneumatic suspension and portal axles allow the driver to choose between 10 and 20 inches of ground clearance. They each feature a 120-kWh lithium-ion battery pack."   https://www.autoblog.com/2020/08/18/bollinger-motors-new-headquarters-oak-park-michigan-staff-to-double   TESLA TAPS TSMC AND BROADCOM FOR 7NM HPC PROCESSOR "The company is reporting teaming with Broadcom to make a new 7nm processor, something known as HW 4.0 -- which will power its next-gen Full Self Driving (FSD) computer. The new 7nm HPC chip will be made on TSMC's 7nm node and will be made later this year -- and put into cars in 2022 and beyond." says TweakTown.com: "Mass production on the new Tesla Motors FSD chip will begin in late 2021, which is mostly because TSMC is absolutely flooded with orders for its 7nm node. AMD is building its entire Ryzen CPU and Radeon GPU families of products on the 7nm node by TSMC, the next-gen Xbox Series X and PlayStation 5 consoles and their semi-custom APUs are being made by TSMC, and so much more on 7nm Tesla Motors' new HW 4.0 chip will also make use of TSMC's Integrated FanOut (InFo) packaging technology, something that will reduce the overall package surface area and allow for lower thermal resistance. It will use TSMC's latest System on Wafer (SoW) technology that doesn't require a substrate and PCB in the entire process."   Is it HW4? Is it Dojo? ie for their servers? Is it both?   https://www.tweaktown.com/news/74584/tesla-taps-tsmc-and-broadcom-for-7nm-hpc-processor-coming-in-2022/index.html   EVERYTHING YOU WANTED TO KNOW ABOUT EVS Owning, Charging, Driving & Saving.   http://newsroom.vw.com/vehicles/everything-you-wanted-to-know-about-evs-but-might-be-afraid-to-ask/   KANDI AMERICA ANNOUNCES DETAILS ON $10K EV FOR USA Kandi is offering a special promotion for the first 1,000 pre-orders for each model. Originally priced at $19,999 MSRP, the K27 is now listed as $17,499. The K23 is discounted from $29,999 MSRP to $27,499. With the $7,500 federal tax credit, this brings the prices down to just $9,999 and $19,999 respectively for eligible buyers. Nationwide pre-orders for the K27 and K23 models can be made at Drive.KandiAmerica.com by submitting a fully-refundable $100 deposit to secure the order. The vehicles will be available for delivery starting in the fourth quarter of 2020. Prospective dealers looking to gain additional information on how to become a Kandi America partner can visit KandiAmerica.com/dealer-inquiry.   K23 - 20kW, 100 miles range, 63 mph, 17.69 kWh. 4 adults.   Find out more at drivekandi.com   NEW TRITIUM 175KW DC FAST CHARGER The electric vehicle (EV) charging experience is now even closer to the speed of a gas station visit with the new DC fast charger from leading provider, Tritium. The RT175-S smart charging system powers EVs to an 80 percent charge in 15 minutes on average and is the first charger on the U.S. market capable of Plug and Charge, a communications protocol enabling electric vehicles and charging equipment to communicate, authenticate and bill customers via the charging cable. No longer will drivers need an RFID membership card, smartphone application or credit card reader to pay for their charge. With Plug and Charge, a charging session can be automatically and securely billed from the moment the plug connects to the vehicle, regardless of the network operator. This advancement in charging technology streamlines and simplifies the charging experience, while improving customer data security.   https://www.prnewswire.com/news-releases/new-tritium-dc-fast-charger-powers-electric-vehicles-to-80-percent-in-15-minutes-301114363.html   ELECTRIFY AMERICA COLLABORATES WITH LOVE’S TRAVEL STOPS "Electrify America, the largest open direct current (DC) fast-charging network in the US will work with Love’s Travel Stops, the US’ industry-leading travel stop network, to bring public ultra-fast electric vehicle (EV) charging stations to seven locations in six US states." says Green Car Congress: "The seven charging stations, located in Oklahoma, New Mexico, Utah, Florida, New York and Arizona, will have a combined 28 EV chargers and be available for public use by early 2021; five locations are already open. The most recent Love’s station opening in Salina, Utah, helped complete a cross-country route of Electrify America chargers spanning from Los Angeles to Washington, D.C. Depending on the location, Love’s customers   will have access to chargers ranging in power from 150 kW to 350 kW."   https://www.greencarcongress.com/2020/08/20200819-ea.html   UK TAKES THE NEXT STEP IN CURBSIDE ELECTRIC VEHICLE CHARGING "World-first technology that could unlock electric vehicle charging for people without driveways or garages is being trialed across London. Startup company Trojan Energy is installing 200 of its chargers across Brent and Camden. Each charge point is slotted into the ground with a flat and flush connection. The technology has no permanent footprint or street clutter as the hardware is only visible when a vehicle is charging." according to Electric Vehicle Research: "The technology consists of 2 parts - a charge point slotted into the ground, and a 'lance' which is inserted into the charge point in order to charge. The charger can provide charge rates from 2kW to 22kW, and up to 18 chargers can run in parallel from one electricity network connection"   https://www.electricvehiclesresearch.com/articles/21466/uk-takes-the-next-step-in-curbside-electric-vehicle-charging   JLR PROGRESSES PROJECT ZEUS TO PUSH FCEV FOR MID-2020 "Jaguar Land Rover is working with partners in the British government-sponsored ‘Zeus’ project to develop fuel cell versions of its larger vehicles. A drivable prototype is to be available shortly." says electrive: "JLR was among the carmakers that benefitted from £73.5 million in funding through the Advanced Propulsion Centre that the British government announced in June. In the case of Jaguar Land Rover, the company is using the money to further project Zeus to develop fuel cell technology. Autocar now reports that progress is being made as the first fuel cell concept to emerge from this project will probably be an SUV the size of the Range Rover Evoque. The next-generation Range Rover Evoque’s arrival is expected in the middle of the 2020s. JLR may then use the fuel cell technology for zero-emissions versions of larger models in the future."   https://www.electrive.com/2020/08/18/jaguar-land-rover-project-zeus-makes-progress-on-fcevs/     You can listen to all 870 previous episodes of this this for free, where you get your podcasts from, plus the blog https://www.evnewsdaily.com/ – remember to subscribe, which means you don’t have to think about downloading the show each day, plus you get it first and free and automatically.   It would mean a lot if you could take 2mins to leave a quick review on whichever platform you download the podcast.   And  if you have an Amazon Echo, download our Alexa Skill, search for EV News Daily and add it as a flash briefing.   Come and say hi on Facebook, LinkedIn or Twitter just search EV News Daily, have a wonderful day, I’ll catch you tomorrow and remember…there’s no such thing as a self-charging hybrid.     PHIL ROBERTS / ELECTRIC FUTURE (PREMIUM PARTNER) BRAD CROSBY (PREMIUM PARTNER) AVID TECHNOLOGY (PREMIUM PARTNER) PORSCHE OF THE VILLAGE CINCINNATI (PREMIUM PARTNER) AUDI CINCINNATI EAST (PREMIUM PARTNER) VOLVO CARS CINCINNATI EAST (PREMIUM PARTNER) NATIONALCARCHARGING.COM and ALOHACHARGE.COM  (PREMIUM PARTNER) DEREK REILLY FROM THE EV REVIEW IRELAND YOUTUBE CHANNEL (PREMIUM PARTNER)   DAVID AND LISA ALLEN (PARTNER) OEM AUDIO OF NEW ZEALAND AND EVPOWER.CO.NZ (PARTNER) GARETH HAMER eMOBILITY NORWAY HTTPS://WWW.EMOBILITYNORWAY.COM/  (PARTNER) BOB BOOTHBY – MILLBROOK COTTAGES AND ELOPEMENT WEDDING VENUE (PARTNER) DARIN MCLESKEY (PARTNER)   ALAN ROBSON (EXECUTIVE PRODUCER) ALAN SHEDD (EXECUTIVE PRODUCER) ALEX BANAHENE (EXECUTIVE PRODUCER) ALEXANDER FRANK @ https://www.youtube.com/c/alexsuniverse42 ANDERS HOVE (EXECUTIVE PRODUCER) ANDREA JEFFERSON (EXECUTIVE PRODUCER) ASEER KHALID (EXECUTIVE PRODUCER) ASHLEY HILL (EXECUTIVE PRODUCER) BÅRD FJUKSTAD (EXECUTIVE PRODUCER) BRENT KINGSFORD (EXECUTIVE PRODUCER) BRIAN THOMPSON (EXECUTIVE PRODUCER) BRUCE BOHANNAN (EXECUTIVE PRODUCER) CHARLES HALL (EXECUTIVE PRODUCER) CHRIS HOPKINS (EXECUTIVE PRODUCER) COLIN HENNESSY AND CAMBSEV (EXECUTIVE PRODUCER) CRAIG COLES (EXECUTIVE PRODUCER) CRAIG ROGERS (EXECUTIVE PRODUCER) DAMIEN DAVIS (EXECUTIVE PRODUCER) DARREN FEATCH (EXECUTIVE PRODUCER) DAVE DEWSON (EXECUTIVE PRODUCER) DAVID FINCH (EXECUTIVE PRODUCER) DAVID MOORE (EXECUTIVE PRODUCER) DAVID PARTINGTON (EXECUTIVE PRODUCER) DAVID PRESCOTT (EXECUTIVE PRODUCER) DON MCALLISTER / SCREENCASTSONLINE.COM (EXECUTIVE PRODUCER) ERU KYEYUNE-NYOMBI (EXECUTIVE PRODUCER) FREDRIK ROVIK (EXECUTIVE PRODUCER) GENE RUBIN (EXECUTIVE PRODUCER) GILBERTO ROSADO (EXECUTIVE PRODUCER) GEOFF LOWE (EXECUTIVE PRODUCER) HEDLEY WRIGHT (EXECUTIVE PRODUCER) IAN GRIFFITHS (EXECUTIVE PRODUCER) IAN SEAR (EXECUTIVE PRODUCER) IAN (WATTIE) WATKINS (EXECUTIVE PRODUCER) JACK OAKLEY (EXECUTIVE PRODUCER) JAMES STORR (EXECUTIVE PRODUCER) JIM MORRIS (EXECUTIVE PRODICERS) JOHN C SOLAR (EXECUTIVE PRODUCER) JON AKA BEARDY MCBEARDFACE FROM KENT EVS (EXECUTIVE PRODUCER) JON MANCHAK (EXECUTIVE PRODUCER) JUAN GONZALEZ (EXECUTIVE PRODUCER) KEN MORRIS (EXECUTIVE PRODUCER) KEVIN MEYERSON (EXECUTIVE PRODUCER) KYLE MAHAN (EXECUTIVE PRODUCER) LARS DAHLAGER (EXECUTIVE PRODUCER) LAURENCE D ALLEN (EXECUTIVE PRODUCER) LEE BROWN (EXECUTIVE PRODUCER) LUKE CULLEY (EXECUTIVE PRODUCER) MARCEL WARD (EXECUTIVE PRODUCER) MARK BOSSERT (EXECUTIVE PRODUCER) MARTY YOUNG  (EXECUTIVE PRODUCER) MATT PISCIONE (EXECUTIVE PRODUCER) MIA OPPELSTRUP (PARTNER) MICHAEL PASTRONE (EXECUTIVE PRODUCER) MIKE WINTER (EXECUTIVE PRODUCER) NATHAN GORE-BROWN (EXECUTIVE PRODUCER) NEIL E ROBERTS FROM SUSSEX EVS (EXECUTIVE PRODUCER) NIGEL MILES (EXECUTIVE PRODUCER) OHAD ASTON (EXECUTIVE PRODUCER) PAUL RIDINGS (EXECUTIVE PRODUCER)               PAUL STEPHENSON (EXECUTIVE PRODUCER) PETE GLASS (EXECUTIVE PRODUCER) PETE GORTON (EXECUTIVE PRODUCER) PETER & DEE ROBERTS FROM OXON EVS (EXECUTIVE PRODUCER)  PHIL MOUCHET (EXECUTIVE PRODUCER) PHILIP TRAUTMAN (EXECUTIVE PRODUCER) RAJ BADWAL (EXECUTIVE PRODUCER) RAJEEV NARAYAN (EXECUTIVE PRODUCER) RENE KEEMIK (EXECUTIVE PRODUCER) RENÉ SCHNEIDER (EXECUTIVE PRODUCER) RICHARD LUPINSKY (EXECUTIVE PRODUCER) ROB HERMANS (EXECUTIVE PRODUCER) ROB FROM THE RSTHINKS EV CHANNEL ON YOUTUBE (EXECUTIVE PRODUCER) RUPERT MITCHELL (EXECUTIVE PRODUCER) SEIKI PAYNE (EXECUTIVE PRODUCER) STEPHEN PENN (EXECUTIVE PRODUCER) STEVE JOHN (EXECUTIVE PRODUCER) THOMAS J. THIAS  (EXECUTIVE PRODUCER) TODD OAKES (EXECUTIVE PRODUCER) THE PLUGSEEKER – EV YOUTUBE CHANNEL (EXECUTIVE PRODUCER) TIM GUTTERIDGE (EXECUTIVE PRODUCER) WILLIAM LANGHORNE (EXECUTIVE PRODUCER)     CONNECT WITH ME! EVne.ws/itunes EVne.ws/tunein EVne.ws/googleplay EVne.ws/stitcher EVne.ws/youtube EVne.ws/iheart EVne.ws/blog EVne.ws/patreon   Check out MYEV.com for more details: https://www.myev.com

Show #854   Good morning, good afternoon and good evening wherever you are in the world, welcome to EV News Daily for Friday 31st July 2020. It’s Martyn Lee here and I go through every EV story so you don't have to.   Thank you to MYEV.com for helping make this show, they’ve built the first marketplace specifically for Electric Vehicles. It’s a totally free marketplace that simplifies the buying and selling process, and help you learn about EVs along the way too.   7,000 RESERVATIONS FOR THE FISKER OCEAN "Fisker, which pins its hopes of rising from the ashes in the Ocean electric SUV, dished out a hard figure to judge just how much interest there is in its upcoming EV. It's nothing spectacular, but there's certainly interest." says CNET: "The company said Friday it has 7,062 reservations for the Ocean. Compared to recent news surrounding preorders (I'm thinking Tesla Cybertruck and Ford Bronco) it's a drop in the bucket. However, it goes to show there is an audience for Fisker's SUV with oodles of sustainable materials inside. The reservations come from 30 countries and Fisker said the figure virtually sells out the first planned production run in late 2022. Additionally, Fisker talked about a second SUV for the first time it dubbed a "sports crossover." The image shows a swoopy design sort of reminiscent of the Volkswagen ID 4. Behind it, the startup also wants to produce a pickup truck."   https://www.cnet.com/roadshow/news/fisker-ocean-electric-suv-reservations-future-models/   VOLKSWAGEN DELAYS DEAL TO SUPPLY A POWERTRAIN FOR HENRIK FISKER'S NEW EV "Buried as almost a passing note in a recent investor presentation by car designer and EV startup founder Henrik Fisker was news that Volkswagen has delayed negotiations to supply powertrain parts for his company’s upcoming Ocean crossover. Sounds like a big problem." according to Jalopnik: "This could be a huge problem for Fisker Inc., as it’s already advertised and sold deposits for a vehicle with certain projected performance—deposits it accepted without even knowing for certain what the fundamental hardware of the vehicle would be. Any major changes from here could mean major changes to the Ocean as advertised. If they’re changes for the worse, expect to refund some deposits."   https://jalopnik.com/volkswagen-delays-deal-to-supply-a-powertrain-for-henri-1844572271   Here’s a statement from Fisker Inc.: "We remain in conversation and parallel development with several industry-leading platform and manufacturing OEMs and suppliers, and will continue to consider any opportunities that would enable us to enter into definitive manufacturing and supply agreements before year-end. We are committed to taking any actions that advance our objective of delivering the Ocean as early as the end of 2022.”"   TESLA RELEASES Q2 2020 SAFETY REPORT "In the 2nd quarter, we registered one accident for every 4.53 million miles driven in which drivers had Autopilot engaged. For those driving without Autopilot but with our active safety features, we registered one accident for every 2.27 million miles driven. For those driving without Autopilot and without our active safety features, we registered one accident for every 1.56 million miles driven. By comparison, NHTSA’s most recent data shows that in the United States there is an automobile crash every 479,000 miles."   In comparison, Tesla had an accident on Autopilot every 3.27 million miles in Q2 2019.   AMERICA’S CHEAPEST ELECTRIC VEHICLES ARE COMING COURTESY OF CHINESE AUTOMAKER KANDI "Chinese electric vehicle and parts manufacturer Kandi Technologies Group  is officially bringing two EVs to the United States through its subsidiary Kandi America — news that has prompted run up in its share price in the past day. " says TEch Crunch: "Kandi Technologies has been talking about bringing EVs to the United States for a couple of years. Now, two models are arriving as early as the end of 2020, beginning in a limited area in Texas. Both are priced under $30,000 before federal incentives. The two models heading to the U.S. are Kandi’s compact K27 vehicle that comes with a 17.69 kWh battery, The larger K23 is also coming to the U.S. market. This small electric SUV has a 41.4 kWh battery and a driving range of more than 180 miles. The K23 starts at just less than $30,000, again, before applying federal incentives."   https://techcrunch.com/2020/07/30/americas-cheapest-electric-vehicles-are-coming-courtesy-of-chinese-automaker-kandi/   AUDI SPORT TO ELECTRIFY EVERY FUTURE RS MODEL "Future Audi RS models will have one powertrain in the future, and it’ll be electrified. According to Audi Sport sales and marketing head Rolf Michl in an Autocar interview about the brand’s intentions, that includes mild-hybrids, plug-ins, and full EVs." reports Motor1: "Both should arrive before 2023 in the form of the RS4 – the plug-in – and the E-Tron GT RS."   https://www.motor1.com/news/436728/audi-sport-electrify-future-rs-models/   LORDSTOWN MOTORS SHOWS OFF ENDURANCE ELECTRIC PICKUP TRUCK IN NEW VIDEO "Lordstown Motors just released a new promotional video with its all-electric pickup - Endurance, scheduled for market launch in 2021 (in Summer 2021 according to what we heard the last time)." says InsideEVs: "The description says: "Keep moving, keep building, keep believing. Endurance will take us forward, because endurance is what got us here. Introducing the all-electric Endurance, by Lordstown Motors.""   https://insideevs.com/news/436695/lordstown-motors-endurance-new-video/   MINI ELECTRIC HITS PRODUCTION MILESTONE MINI Plant Oxford has built more than 11,000 MINI Electrics since production began More than 3,000 MINI Electric orders in the UK to date UK is second largest market for electrified MINI models with 19 per cent sales share for MINI Electric and Countryman Plug-In Hybrid In 2021, a third of MINI 3-Door Hatch models built is expected to be elec   MAHLE AIMS FOR FASTER CHARGING WITH BETTER CONDENSER "Mahle has presented a new type of condenser for cooling systems in hybrid and electric vehicles that should enable faster charging of the traction battery." reports Electrive: "The development of the new condenser was been prompted by the increase in overall demands on cooling systems in hybrid and electric vehicles where the battery, power electronics, electric motors and other components must all be kept within a carefully defined temperature window."   https://www.electrive.com/2020/07/30/mahle-aims-for-faster-charging-with-better-capacitor/   LINK TRANSIT’S 10 NEW BYD BUSES COME WITH WIRELESS CHARGING "BYD is back to building electric buses. The company’s first post-closure delivery completed an order of 10 battery-electric K9S buses to Link Transit in Wenatchee, Washington." says ChargedEvs: The K9S 35-ft electric bus seats up to 32, has a range of 215 miles, and can be charged in 3 to 4 hours. Link Transit’s 10 buses are fitted with wireless charging receivers from Momentum Dynamics, to allowing for en route charging. . In January, Momentum and Link Transit extended their relationship with a new five-year agreement under which Momentum will provide three new 300 kW en route charging stations."   https://chargedevs.com/newswire/link-transits-10-new-byd-buses-come-with-momentum-dynamics-wireless-charging-system/   4 NEW ELECTRIC VANS JUST HIT THE UK & EUROPEAN MARKETS Peugeot e-Expert & Citroën ë-Dispatch - You can now order the e-Expert in the UK, with a starting price of £25,053 (excluding VAT but after the Plug-in Van Grant) Renault ZOE Van - “The All-New ZOE Van is capable of travelling up to 245 miles on a charge, and uses the same powerful 52kWh battery pack and 80kW R110 electric motor as the New ZOE supermini.” Mercedes-Benz EQV - Mercedes-Benz, the EQV, comes with a hefty price tag. Starting prices for the different trims are: EQV 300 Sport — £70,665. 90 kWh battery with 213 miles of range (WLTP).   https://cleantechnica.com/2020/07/30/4-new-electric-vans-just-hit-the-uk-european-markets/     You can listen to all 853 previous episodes of this this for free, where you get your podcasts from, plus the blog https://www.evnewsdaily.com/ – remember to subscribe, which means you don’t have to think about downloading the show each day, plus you get it first and free and automatically.   It would mean a lot if you could take 2mins to leave a quick review on whichever platform you download the podcast.   And  if you have an Amazon Echo, download our Alexa Skill, search for EV News Daily and add it as a flash briefing.   Come and say hi on Facebook, LinkedIn or Twitter just search EV News Daily, have a wonderful day, I’ll catch you tomorrow and remember…there’s no such thing as a self-charging hybrid.     PHIL ROBERTS / ELECTRIC FUTURE (PREMIUM PARTNER) BRAD CROSBY (PREMIUM PARTNER) AVID TECHNOLOGY (PREMIUM PARTNER) BRIGHTSMITHGROUP.COM – FOR CLEANTECH TALENT (PREMIUM PARTNER) PORSCHE OF THE VILLAGE CINCINNATI (PREMIUM PARTNER) AUDI CINCINNATI EAST (PREMIUM PARTNER) VOLVO CARS CINCINNATI EAST (PREMIUM PARTNER) NEW! NATIONALCARCHARGING.COM and ALOHACHARGE.COM  (PREMIUM PARTNER)   DAVID AND LISA ALLEN (PARTNER) OEM AUDIO OF NEW ZEALAND AND EVPOWER.CO.NZ (PARTNER) PAUL O’CONNOR (PARTNER) TRYEV.COM (PARTNER) GARETH HAMER eMOBILITY NORWAY HTTPS://WWW.EMOBILITYNORWAY.COM/  (PARTNER) BOB BOOTHBY – MILLBROOK COTTAGES AND ELOPEMENT WEDDING VENUE (PARTNER) EV-RESOURCE.COM   ALAN ROBSON (EXECUTIVE PRODUCER) ALAN SHEDD (EXECUTIVE PRODUCER) ALEX BANAHENE (EXECUTIVE PRODUCER) ALEXANDER FRANK @ https://www.youtube.com/c/alexsuniverse42 ANDERS HOVE (EXECUTIVE PRODUCER) ANDREA JEFFERSON (EXECUTIVE PRODUCER) ASEER KHALID (EXECUTIVE PRODUCER) ASHLEY HILL (EXECUTIVE PRODUCER) BÅRD FJUKSTAD (EXECUTIVE PRODUCER) BRENT KINGSFORD (EXECUTIVE PRODUCER) BRIAN THOMPSON (EXECUTIVE PRODUCER) BRUCE BOHANNAN (EXECUTIVE PRODUCER) CHARLES HALL (EXECUTIVE PRODUCER) CHRIS HOPKINS (EXECUTIVE PRODUCER) COLIN HENNESSY AND CAMBSEV (EXECUTIVE PRODUCER) CRAIG COLES (EXECUTIVE PRODUCER) CRAIG ROGERS (EXECUTIVE PRODUCER) DAMIEN DAVIS (EXECUTIVE PRODUCER) DARREN FEATCH (EXECUTIVE PRODUCER) DARREN SANT FROM YORKSHIRE EV CLUB (EXECUTIVE PRODUCER) DAVE DEWSON (EXECUTIVE PRODUCER) DAVID BARKMAN (EXECUTIVE PRODUCER) DAVID FINCH (EXECUTIVE PRODUCER) DAVID MOORE (EXECUTIVE PRODUCER) DAVID PARTINGTON (EXECUTIVE PRODUCER) DAVID PRESCOTT (EXECUTIVE PRODUCER) DEREK REILLY FROM THE EV REVIEW IRELAND YOUTUBE CHANNEL (EXECUTIVE PRODUCER) DON MCALLISTER / SCREENCASTSONLINE.COM (EXECUTIVE PRODUCER) ENRICO STEPHAN-SCHILOW (EXECUTIVE PRODUCER) ERU KYEYUNE-NYOMBI (EXECUTIVE PRODUCER) FREDRIK ROVIK (EXECUTIVE PRODUCER) FREEJOULE AKA JAMES (EXECUTIVE PRODUCER) GENE RUBIN (EXECUTIVE PRODUCER) GILBERTO ROSADO (EXECUTIVE PRODUCER) GEOFF LOWE (EXECUTIVE PRODUCER) HEDLEY WRIGHT (EXECUTIVE PRODUCER) IAN GRIFFITHS (EXECUTIVE PRODUCER) IAN SEAR (EXECUTIVE PRODUCER) IAN (WATTIE) WATKINS (EXECUTIVE PRODUCER) JACK OAKLEY (EXECUTIVE PRODUCER) JAMES STORR (EXECUTIVE PRODUCER) JERRY ALLISON (EXECUTIVE PRODUCER) JIM DUGAN (EXECUTIVE PRODUCER) JIM MORRIS (EXECUTIVE PRODICERS) JOHN BAILEY (EXECUTIVE PRODUCER) JOHN C SOLAR (EXECUTIVE PRODUCER) JOHN LACEY FROM CLICK CLACK VIDEO NZ (EXECUTIVE PRODUCER) JON AKA BEARDY MCBEARDFACE FROM KENT EVS (EXECUTIVE PRODUCER) JON MANCHAK (EXECUTIVE PRODUCER) JUAN GONZALEZ (EXECUTIVE PRODUCER) KEN MORRIS (EXECUTIVE PRODUCER) KEVIN MEYERSON (EXECUTIVE PRODUCER) KYLE MAHAN (EXECUTIVE PRODUCER) LARS DAHLAGER (EXECUTIVE PRODUCER) LAURENCE D ALLEN (EXECUTIVE PRODUCER) LEE BROWN (EXECUTIVE PRODUCER) LUKE CULLEY (EXECUTIVE PRODUCER) MARCEL LOHMANN (EXECUTIVE PRODUCER) MARCEL WARD (EXECUTIVE PRODUCER) MARK BOSSERT (EXECUTIVE PRODUCER) MARTIN CROFT DORSET TRADESMEN MARTY YOUNG  (EXECUTIVE PRODUCER) MATT PISCIONE (EXECUTIVE PRODUCER) MAZ SHAR (EXECUTIVE PRODUCER) MICHAEL AND LUKE TURRELL (EXECUTIVE PRODUCER) MIA OPPELSTRUP (PARTNER) MICHAEL PASTRONE (EXECUTIVE PRODUCER) MIKE ROGERS (EXECUTIVE PRODUCER) MIKE WINTER (EXECUTIVE PRODUCER) NATHAN GORE-BROWN (EXECUTIVE PRODUCER) NEIL E ROBERTS FROM SUSSEX EVS (EXECUTIVE PRODUCER) NIGEL MILES (EXECUTIVE PRODUCER) NORTHERN EXPLORERS (EXECUTIVE PRODUCER) OHAD ASTON (EXECUTIVE PRODUCER) PAUL RIDINGS (EXECUTIVE PRODUCER)               PAUL STEPHENSON (EXECUTIVE PRODUCER) PERRY SIMPKINS (EXECUTIVE PRODUCER) PETE GLASS (EXECUTIVE PRODUCER) PETE GORTON (EXECUTIVE PRODUCER) PETER & DEE ROBERTS FROM OXON EVS (EXECUTIVE PRODUCER)  PHIL MOUCHET (EXECUTIVE PRODUCER) PHILIP TRAUTMAN (EXECUTIVE PRODUCER) PONTUS KINDBLAD (EXECUTIVE PRODUCER) RAJ BADWAL (EXECUTIVE PRODUCER) RAJEEV NARAYAN (EXECUTIVE PRODUCER) RALPH JENSON (EXECUTIVE PRODUCER) RENE KEEMIK (EXECUTIVE PRODUCER) RENÉ SCHNEIDER (EXECUTIVE PRODUCER) RICHARD LUPINSKY (EXECUTIVE PRODUCER) ROB COOLING / HTTP://WWW.APPLEDRIVING.CO.UK/ (EXECUTIVE PRODUCER) ROB HERMANS (EXECUTIVE PRODUCER) ROB FROM THE RSTHINKS EV CHANNEL ON YOUTUBE (EXECUTIVE PRODUCER) ROBERT GRACE (EXECUTIVE PRODUCER) ROBIN TANNER (EXECUTIVE PRODUCER) RUPERT MITCHELL (EXECUTIVE PRODUCER) SARI KANGASOJA (EXECUTIVE PRODUCER) SEIKI PAYNE (EXECUTIVE PRODUCER) STEPHEN PENN (EXECUTIVE PRODUCER) STEVE JOHN (EXECUTIVE PRODUCER) THOMAS J. THIAS  (EXECUTIVE PRODUCER) THE PLUGSEEKER – EV YOUTUBE CHANNEL (EXECUTIVE PRODUCER) TIM GUTTERIDGE (EXECUTIVE PRODUCER) WILLIAM LANGHORNE (EXECUTIVE PRODUCER)     CONNECT WITH ME! EVne.ws/itunes EVne.ws/tunein EVne.ws/googleplay EVne.ws/stitcher EVne.ws/youtube EVne.ws/iheart EVne.ws/blog EVne.ws/patreon   Check out MYEV.com for more details: https://www.myev.com

People who experience weight discrimination are more likely to gain more weight over time than people with obesity who don't describe these kinds of experiences. Weight bias, stigma and discrimination have received more and more attention among researchers, but also in the public. Think, for example, of the term "fat shaming." Among the researchers doing pathbreaking work in this area is Dr. Rebecca Pearl at the Perlman School of Medicine. Her research focuses on weight bias and its associated outcomes in patients with obesity. About Rebecca Pearl Rebecca Pearl, PhD, is an Assistant Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania. She received her BA from Duke University and her PhD in clinical psychology from Yale University. She completed her predoctoral psychology internship at McLean Hospital/Harvard Medical School and her postdoctoral fellowship at the Penn Center for Weight and Eating Disorders. Her research focuses on weight bias and its associated health outcomes in patients with obesity. She also investigates strategies for reducing weight bias and its internalization. Her work has been recognized with awards from The Obesity Society and the American Psychological Association and is currently supported by a K23 mentored patient-oriented research career development award from the National Heart, Lung and Blood Institute of the NIH. Interview Summary Rebecca, I'm very grateful that you could join us, and let me start with a fundamental question. What is weight bias? How do you define it? Well, Kelly, first, thank you so much for having me, and it's a real treat to speak with you about this topic considering that you are one of the first people to really draw attention to this issue, especially in the scientific context. So when we're talking about weight bias, we're thinking about negative attitudes toward people because of their weight, so people with overweight and obesity, and these negative attitudes are rooted in some common stereotypes, such as that people with obesity are lazy, they don't have any self control, they're unhealthy or don't care about their health. They're greedy, or might even be less intelligent than other people. And then there's also a strong sense of blame that's put on people because of their weight, due to this belief that weight should be entirely within an individual's control. So when people are perceived as not being able to control their weight, they're perceived as being a weak person, or having weak character, or having a failure of personal responsibility. So actually being perceived as an irresponsible person because they have a higher body weight, and these negative attitudes and stereotypes and this blame lead people with obesity to face societal stigma, experiences of weight-based teasing or bullying, discrimination or social rejection, or just generally being devalued by society. And these consequences can be pretty severe, can't they? Absolutely. From a socioeconomic level, when people are denied employment opportunities or denied promotions because of their weight, that can affect wages and socioeconomic advancement. There are also educational disparities that can be attributed to weight bias and weight-based discrimination, and then there are also a number of health disparities that might be in part explained by experiences of weight discrimination or stigmatization. So we'll come back to the health issues in just a minute, but I want to ask you about a particularly important area that you've worked on, weight bias internalization. You and others have documented the impact on people, but you've looked at this particular issue in great depth about internalization. Can you tell us what you mean by that? People can experience weight bias from other people, but they can also apply it to themselves. So weight bias internalization is sometimes called self-directed stigma, and this occurs when people with obesity are aware of the negative attitudes and stereotypes about people with a higher body weight. People with obesity might come to also believing that they are a weak person, or lazy, or a failure, or less worthy than other people, so it's really how stigma can get under the skin, if you will, when people are devaluing themselves because of their weight. And is there variability in how much people with obesity do internalize these negative messages? And what effects does that have when somebody does? Not everybody with obesity internalizes weight bias, but given how pervasive the societal messages are about weight, it's understandable when people do internalize these messages. There's certainly a significant minority of people who have high levels of internalized weight bias, and then many more people who internalize these messages, at least to some degree. A lot of the same health effects that we see from experiencing discrimination from other people, we're also seeing independently associated with this internalized weight bias, and some studies actually suggest that weight bias internalization, above and beyond the experiences of weight bias, might be a stronger predictor of some of the negative health outcomes. So let's loop back to that issue of weight bias and health. And one could imagine that if you internalize the bias and-or you're just subjected to all these things happening out there in society, and it affects your wages, your success in education and all these other kinds of things, that it could affect your health through things like depression and stress. Are there other ways that weight bias might affect health? So those are the big ones. We do know people have higher rates of depression when they're reporting experiences of weight discrimination. Also more anxiety disorders, which makes sense too if you think about when people are anticipating rejection or anticipating discrimination, that that is stressful and might also increase anxiety, especially in social interactions. We also know that substance use disorders are higher in people who have perceived weight discrimination. And then the stress issue is a big one that more and more researchers have been looking at. There's a physiological stress as well as a psychological distress that might affect health outcomes. So if we see changes in cortisol, blood pressure, other markers of inflammation, and those independently are risk factors for cardiovascular disease, but those can also affect people's appetite. So cortisol, for example, is a hormone in relation to stress that can increase appetite, so people might also have behavioral responses to these experiences or even just the internalization of weight bias that's in part driven by physiological responses of eating more food because their body is in a state of stress. So many of us eat as a way of coping with negative emotions, as a way of soothing ourselves or finding comfort. And so for a lot of people who experience weight bias, this is a common way of coping. People also might avoid engaging in physical activity when they are concerned about how others might be perceiving them because of their weight. Especially in public settings like in a gym, they might feel intimidated or just very self-conscious. The patients I've worked with have described negative comments that they've received in fitness type settings, so that would understandably lead them to want to avoid being in those settings. And so that combination of eating more food in response to these experiences as well as avoiding physical activity can actually lead to more weight gain over time. And the last aspect of health that is really important to highlight is how weight bias can play out in health care. So many patients describe having humiliating or disparaging experiences in health care settings, and this might not be intentional on the part of the physician. They might not even be aware of the bias. So for example, a patient coming in for a health concern that's completely unrelated to weight, and the physician solely focusing on the need to lose weight. That can be a very frustrating experience for a patient that might make them want to avoid even bothering to go to the doctor's office the next time they have any health concern. And so if patients are avoiding health care settings, then that's also setting up a higher risk for missing health problems early or for missing out on preventative healthcare services. And the quality of care, too, can also be influenced by weight bias. So Rebecca, what strategies do you think might be effective for reducing weight bias? There are some structural level interventions that have been showing promise. So these interventions include changing media portrayals to reduce the stereotypical or stigmatizing images, and news content in stories about obesity. Other interventions might include policies, for example, legislation to prohibit weight discrimination. In most cities and states in the United States, with the exception of a few cities and one state, the state of Michigan, it is entirely legal to discriminate against hiring or promoting someone because of their weight, so policies to address that could be very effective at reducing instances of discrimination, as well as anti-bullying laws that specifically incorporate weight as a reason that bullying is prohibited. And then other policies at institutional levels within workplaces or educational settings or healthcare settings to promote awareness of body size diversity and increase weight sensitivity by incorporating more education about obesity, especially in healthcare settings, might be helpful as well. Obesity is tied to biological factors, to environmental factors, and it's not a matter of personal weakness or a failure of personal responsibility. There are so many complex factors that influence a person's weight. Some of that kind of education might be helpful for increasing understanding and reducing bias. Another principle that's been looked at is the idea of social consensus as well. Weight is a very socially acceptable thing to tease people about or to stigmatize people for, and so if we could figure out ways, whether it would be through campaigns or just individual actions of making it clear that it is not acceptable to tease someone or make someone feel badly about themselves because of their weight, then that could also go a long way in shifting societal attitudes and behaviors. Well, thanks for those ideas. They're really very promising roads to go down. So let me ask one final question. Is there a way to reduce the internalization of these messages in people with obesity? That's a question I've been very interested in in the past few years, and I do want to emphasize that we need to be, first and foremost, trying to improve societal attitudes and behaviors to try to prevent experiences of weight bias or prevent people from internalizing these messages. And for the people who have already internalized these messages, I think it's really important to develop strategies to help them cope with this and to try to retrain their brains or undo some of this internalized weight bias. So some of the strategies that myself and my colleagues have been testing draw upon psychological principles and psychological treatments that have been used for things like depression and anxiety, and trying to adapt those strategies specifically for targeting internalized weight bias. So this might include cognitive and behavioral skills like examining myths and stereotypes about weight and really digging into, what is the evidence that would support a stereotype like people with obesity are lazy? And what are some of the points of evidence that might poke holes in that idea, or to really challenge the evidence against this idea? Other strategies might include learning how to speak up for oneself, so promoting assertiveness skills. If someone does make a comment to you about your weight, how do you respond? What do you say? How do you have a conversation with a loved one to ask them to stop making comments about what you're eating or what your weight is at the dinner table? And other skills like increasing self-compassion, improving body image, these are all strategies that we're looking at to see if they could have an effect on reducing weight bias internalization. And the last potential strategy might be engaging in advocacy as a way of feeling empowered to do something about this social injustice in the world, that that might help people feel better about themselves and also help to combat this bigger problematic issue in society  

Dr. Panigrahy is board certified in both Pediatric Radiology and Neuroradiology.  He is a Professor of Radiology, Radiologist-in-Chief at  Children’s Hospital of Pittsburgh and Vice Chair of Clinical and Translational Imaging Research at UPMC. He has been continuously funded by the NIH since 2009 including both a K23 and current multi-center Ro1. He also has active funding from the Department of Defense, Society for Pediatric Radiology and private foundations.  Dr. Panigrahy’s research focuses on applying advanced MR techniques to the study of fetal/neonatal/pediatric brain development and injury in those diagnosed with congenital heart disease and its impact on neuro-developmental across the lifespan.

durée : 00:14:05 - Scarlatti 555 - Enregistrées durant le Festival Radio France Occitanie Montpellier l'été dernier, écoutons la Sonate K22 en do mineur, la K23 en ré Majeur ainsi que la K24 en la Majeur par trois clavecinistes hors-pair !

1) GABAB receptor autoantibody frequency in-service serological evaluation and 2) This week's topic: About Ted Burns about being diagnosed with a serious cancer. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Zsofia Hole interviews Dr. Andrew McKeon about his paper on GABAB receptor autoantibody frequency in-service serological evaluation. Dr. Roy Strowd is reading our e-Pearl of the week about Fazio-Londe syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Ted Burns about being diagnosed with a serious cancer and how he has gained insight into what it's like being a patient. The participants had nothing to disclose except Drs. McKeon, Strowd, Espay, and Burns.Dr. McKeon receives research support from the Guthy Jackson Charitable Foundation.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.

1) Optic nerve head component responses of multifocal electroretinogram in MS and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Beau Bruce interviews Drs. Teresa and Elliot Frohman about their paper on optic nerve head component responses of multifocal electroretinogram in MS. Dr. Adam Numis is reading our e-Pearl of the week about Terson's syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. John Trojanowski about progressive accumulation of tau pathology in patients with Alzheimer disease and how it occurred in a stereotypical manner. The participants had nothing to disclose except Drs. Bruce, Teresa Frohman, Eliot Frohman, Numis, Espay, and Trojanowski.Dr. Bruce is a consultant for Kaiser Permanente of Georgia for the CDC Vaccine Safety Datalink; receives research support from Novartis, Pfizer Inc, TEVA Pharmaceutical Industries, Ltd and the NIH; and was a recipient of the Practice Research Fellowship.Dr. Teresa Frohman serves as an editorial board member of National Multiple Sclerosis Society; is a consultant for Acorda, Novartis; serves on the speakers' bureau of Acorda Therapeutics, Inc., Novartis; receives royalties from the publication of Up-to-Date; received funding for travel from Acorda Therapeutics Inc., Novartis; received research support from the National Multiple Sclerosis Society and the NIH.Dr. Elliot Frohman is a consultant for TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics, Inc., Novartis, Genzyme Corporation, Abbott; serves on the speakers' bureau of TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis; receives royalties from the publication of Up-to-Date; and received funding for travel from TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Trojanowski serves as an Associate Editor for Alzheimer & Dementia; received research support from The Marian S. Ware Alzheimer Program, Benaroya and the NIH; holds 14 patents that may accrue revenue: US Patent 5,281,521, issued 25 Jan 1994: US Patent 5,580,898, issued 3 Dec 1996; US Patent 5,601,985, issued 11 Feb 1997; US Patent 5,733,734, issued 31 Mar 1998; US Patent 5,792,900, issued 11 Aug 1998; US Patent 5,849,988, issued 15 Dec 1998: US Patent 6,214,334, issued 10 Apr 2001; US Patent 6,358,681, issued 19 Mar 2002; US Patent 6,727,075, issued 27 Mar 2004; US Patent 7,011,827, issued 14 Mar 2006; Penn 0652, K1828, filed 5 Aug 1998; Penn L1986, Filed 13 Nov 1998; Penn R3868 (UPN-4439), filed 28 Feb 2005 and Penn S-4018, DB&R 46406- 217282, filed 22 Nov 2005: Treatment of Alzheimer's and Related Diseases with an Antibody and may accrue revenue in the future on patents submitted by the University of Pennsylvania as co-Inventor and received revenue from the sale of Avid to Eli Lilly and Company as co-inventor on imaging related patents submitted by the University of Pennsylvania while receiving research support from the NIH, Bristol-Myers Squibb, AstraZeneca and several non-profits.

1) Evidence-based guideline: Treatment of tardive syndromes and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Drs. Roongroj Bhidayasiri and Gary Gronseth about the AAN evidence-based guideline on treatment of tardive syndromes. Dr. Roy Strowd is reading our e-Pearl of the week about CTA spot sign. In the next part of the podcast Dr. Alberto Espay interviews Dr. Marsel Mesulam about his H. Houston Merritt Lecture on the selective cognitive impairments and distinct neuropathological entities of the primary progressive aphasias. The participants had nothing to disclose except Drs. Bhidayasiri, Gronseth, Strowd, Espay and Mesulam.Dr. Bhidayasiri served as Editor-in-Chief for The Thai Journal of Neurology; serves on the scientific advisory board for Ministry of Public Heath, Thailand and Excellence Network; serves as Director of Chulalongkorn Center of Excellence on Parkinson's Disease and Related Disorders, Thai Red Cross Society; received funding for trips from BL Hua, GlaxoSmithKline, Medtronic, Inc., Roche; serves on the speakers' bureau of Abbott, BL Hua, Boehringer-Ingelheim, GlaxoSmithKline, Medtronic, Inc., Novartis, Roche; receives royalties from the publication of the books Neurological Differential diagnosis, International Neurology, Movement Disorders: A video atlas; receives research support from Abbott, Immunocal Thailand, Chulalongkorn University, Bangkok, Thailand, Thailand Research Fund and Thai Red Cross Society.Dr. Gronseth serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Mesulam serves on the scientific advisory board for Cure Alzheimer Fund and Association on Frontotemporal Dementia; serves as an editorial board member of Brain, Annals of Neurology, Human Brain Mapping, Journal of Cognitive Neuroscience; receives royalties from the publication of the book Principles of Behavioral and Cognitive Neurology and receives research support from the NIH.

1) Rasmussen's encephalitis treated with natalizumab and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Prof. Heinz Wiendl about his paper on Rasmussen's encephalitis treated with natalizumab. Dr. Roy Strowd is reading our e-Pearl of the week about watching for Whipple's: Oculomasticatory myorhythmia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Pooja Khatri on intra-arterial therapy being used as standard treatment for acute stroke. The participants had nothing to disclose except Prof. Wiendl, Drs. Strowd, Espay and Khatri.Prof. Wiendl received honoraria for travel to attend meetings from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi- Aventis, Schering-Plough Corp., Merck Serono, Teva Pharmaceuticals Industries Ltd.; has served as a consultant or is currently a consultant for Merck Serono, Medac, Inc, Sanofi-aventis, Biogen Idec, Bayer Schering Pharma, Novartis, Teva Pharmaceuticals Industries Ltd., Novo Nordisk; receives research support from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi-aventis, Merck Serono, Teva Pharmaceuticals Industries Ltd., Novartis, Medac, Inc, Genzyme and Novo Nordisk.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Khatri received funding for a trip from Genetech, Inc.; provided expert witnessing for stroke cases over last two years; receives research support from Penumbra, Inc and the NIH.

1) Development and validation of a clinical guideline for diagnosing blepharospasm and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Giovanni Defazio about his paper on development and validation of a clinical guideline for diagnosing blepharospasm. Dr. Roy Strowd is reading our e-Pearl of the week about iatrogenic botulism. In the next part of the podcast Dr. Alberto Espay interviews Dr. Salvatore DiMauro about his Robert Wartenberg Lecture on Mitochondrial encephalomyopathies: 50 years on. The participants had nothing to disclose except Drs. Defazio, Strowd, Espay and DiMauro.Dr. Defazio receives research support from the Italian Ministry of University and Comitato Promotore Telethon.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. DiMauro serves as an editorial board member of Muscle and Nerve, Neuromuscular Disorders, Acta Myologica, MedLink Neurology; serves on the scientific advisory board for Telethon Italia; receives research support from the Muscular Dystrophy Association, Marriott Mitochondrial Disorder Clinical Research Fund and the NIH.

1) Surveillance neuroimaging and neurologic examinations affecting care for intracerebral hemorrhage and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Matthew Maas about his paper on surveillance neuroimaging and neurologic examinations affecting care for intracerebral hemorrhage. Dr. Roy Strowd is reading our e-Pearl of the week about dopamine dysregulation syndrome in Parkinson disease. In the next part of the podcast Dr. Alberto Espay interviews Drs. Stephen Reich and C. Warren Olanow on levodopa being initiated at time of diagnosis of movement disorders. The participants had nothing to disclose except Drs. Maas, Strowd, Espay, Olanow and Reich.Dr. Maas receives research support from the NIH.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Olanow serves as Chief Editor for Movement Disorders; serves on the scientific advisory board for Michael J. Fox Foundation, TEVA Pharmaceutical Industries Ltd, Ceregene; is a consultant for TEVA Pharmaceutical Industries Ltd, Lundbeck, Inc., Novartis, Impax Pharmaceuticals, Ceregene, Orion; holds stock options in Ceregene and Clintrex, receives research support from Ceregene and participated in legal proceedings involving welding defense.Dr. Reich receives royalties from the publication of the book Movement Disorders: 100 Instructive Cases; receives research support from Chiltern, Synosia pharmaceuticals, Phytopharm and the NIH.

1) Depressive symptoms and white matter dysfunction in retired NFL players with concussion history and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Christopher Giza interviews Dr. John Hart about his paper on depressive symptoms and white matter dysfunction in retired NFL players. Dr. Adam Numis is reading our e-Pearl of the week about ice-cream headache. In the next part of the podcast Dr. Alberto Espay interviews Drs. Ron Postuma and Brad Boeve about clinicopathologic correlations in 172 cases of REM sleep behavior disorder. The participants had nothing to disclose except Drs. Giza, Hart, Numis, Espay, Postuma and Boeve.Dr. Giza serves on the data safety monitoring board for LAbiomed Institute at Harbor-UCLA Medical Center; is a consult for NHL Player's Association; serves on the speakers' bureau for the Medical Education Speakers Network; receives royalties from the publication of the book Neurological Differential Diagnosis: A prioritized approach; received funding for travel to Major League Soccer Concussion Committee meeting, California State Athletic Commission Meetings and NCAA meeting; receives research funding from NIH, UCLA faculty grants, Thrasher Research Foundation, NFL Charities, Today's and Tomorrow's Children Fund, Richie's Fund and NCAA, and gave expert testimony on several mediocolegal cases.Dr. Hart serves as an editorial board member of Neurocase, Journal of Innovative Optical Health, World Journals of Radiology and Psychiatry, Frontiers in Neuropsychiatric Imaging and Stimulation; receives royalties from the publication of the book Neural Basis of Semantic Memory; receives research support from the Department of Defense, Alzheimer's Association, RGK Foundation and NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Postuma serves on the scientific advisory board for TEVA Pharmaceutical Industries Ltd; serves as an editorial board member of Movement Disorders Journal and Journal of Caffeine Research; receives honoraria from Allergan, Inc., Novartis, TEVA Pharmaceutical Industries Ltd; receives research support from the Canadian Institute of Health Research, Parkinson Society of Canada, Fonds de Recherche de la Sante Quebec, Weston Foundation and Drummond Foundation.Dr. Boeve has served as an investigator for clinical trials sponsored by Cephalon, Inc., Allon Pharmaceuticals and GE Healthcare; receives royalties from the publication of a book Behavioral Neurology of Dementia; received honoraria from the American Academy of Neurology; serves on the scientific advisory board of the Tau Consortium and receives research support from the National Institute on Aging and the Mangurian Foundation.

1) Guideline update: Evaluation and management of concussion in sports and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Christopher Giza about this guideline update on evaluation and management of concussion in sports. Dr. Adam Numis is reading our e-Pearl of the week about anti -MuSK antibody myasthenia gravis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Merit Cudkowicz about her plenary session on ALS pathways to treatments. The participants had nothing to disclose except Drs. Goodkin, Giza, Numis, Espay and Cudkowicz.Dr. Goodkin serves as an editorial board member of Neurology and Surgical Neurology International; receives royalties from Up-to-Date for co-authorship of The Choking Game and other strangulation activities in children and adolescents; receives research support from the NIH.Dr. Giza serves on the data safety monitoring board for LAbiomed Institute at Harbor-UCLA Medical Center; is a consult for NHL Player's Association; serves on the speakers' bureau for the Medical Education Speakers Network; receives royalties from the publication of the book Neurological Differential Diagnosis: A prioritized approach; received funding for travel to Major League Soccer Concussion Committee meeting, California State Athletic Commission Meetings and NCAA meeting; receives research funding from NIH, UCLA faculty grants, Thrasher Research Foundation, NFL Charities, Today's and Tomorrow's Children Fund, Richie's Fund and NCAA, and gave expert testimony on several mediocolegal cases.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Cudkowicz is a consultant for TEVA Pharmaceutical Industries Ltd., Cytokinetics, Biogen Idec; receives research support from Muscular Dystrophy Association, Amyotrophic Lateral Sclerosis Association, American Telemedicine Association and the NIH.

1) Creation of the AAN Global Health Section and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Amy Lee about her paper on the creation of the AAN Global Health Section. Dr. Adam Numis is reading our e-Pearl of the week about Tullio phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Jerome Posner about receiving the 2013 President's Award at the AAN Meeting and discussing his lecture on the importance of teaching and mentoring in neurology. The participants had nothing to disclose except Drs. Mateen, Numis, Espay and Posner.Dr. Mateen has consulted for the World Health Organization, Global Polio Eradication Initiative, and Caritas.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Posner serves as an editorial board member on Up-to-Date; receives royalties from the publications of the books Diagnosis of stupor and coma and Neurologic complications of cancer; receives royalty payments, technology/inventions from Athena diagnostics.

1) Prevention of new brain lesions and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Pearce Korb interviews Dr. David Mohr about his paper on stress management for the prevention of new brain lesions. Dr. Jennifer Fugate is reading our e-Pearl of the week about Panayiotopoulos syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Chris Austin about his plenary session on translational therapeutics development at NIH. The participants had nothing to disclose except Drs. Mohr, Fugate, and Espay.Dr. Mohr is a consultant for the NIH and receives research support from NIH.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.

1) Stroke thrombolysis and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Atte Meretoja about her paper on reducing in-hospital delay. Dr. Jennifer Fugate is reading our e-Pearl of the week about mytonic dystrophy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Reisa Sperling about her plenary session on molecular and functional imaging detection of preclinical Alzheimer disease. The participants had nothing to disclose except Drs. Meretoja, Fugate, Espay and Sperling.Dr. Meretoja has served as a consultant for Boehringer Ingelheim, and has received honoraria from Boehringer Ingelheim for speaking at educational symposia, travel expenses from H Lundbeck A/S, and research support from Sigrid Juselius Foundation, Biomedicum Helsinki Foundation, Instrumentarium Science Foundation, Yrjo Jahnsson Foundation, Paivikki and Sakari Sohlberg Foundation, Maire Taponen Foundation, Finnish-Norwegian Medical Foundation and Emil Aaltonen Foundation.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Sperling received a speaker honorarium from Pfizer Inc.; serves on the editorial board of Alzheimer¹s disease and Associated Disorders; has served as a consultant for Roche, Janssen, Pfizer Inc, Bayer Schering Pharma, Eisai Inc., Satori, Kyowa Hakko Kirin, Bristol-Myers Squibb and Avid Radiopharmaceuticals, (unpaid); has received research support from Janssen, and Bristol-Myers Squibb, NIH/NIA, Alzheimer¹s Association, American Health Assistance Foundation, and an Anonymous Foundation.

1) Anterior disconnection syndrome and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Drs. Ana Pereira and Alvardo Pascual-Leone about their paper on the anterior disconnection syndrome. Dr. Jennifer Fugate is reading our e-Pearl of the week about normal pressure hydrocephalus. In the next part of the podcast Dr. Alberto Espay interviews Dr. Richard Bedlack about his plenary session on contemporary clinical issues. The participants had nothing to disclose except Drs. Waugh, Pascual-Leone, Fugate, Espay and Bedlack.Dr. Waugh serves as an editorial board member of the Journal of Pediatric Biochemistry.Dr. Pascual-Leone serves on the scientific advisory board for Nexstim, NeoSync, Starlab, Neuronix, Allied minds and NovaVision, inc.; serves as an Associate Editor for European Journal of Neuroscience and Frontiers in Neuroscience; is listed as co-inventor in several patents related to real-time integration of TMS with EEG and functional imaging; receives research support from Nexstim, Neuronix, NIH, The Michael J. Fox Foundation, Berenson-Allen Foundation and RJG Family Foundation.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Bedlack serves on the scientific advisory board DSMB for the ceftriaxone ALS trial; serves on the speakers' bureau of Pfizer Inc, Eli Lilly and Company, Athena Diagnostics and Avanir Pharmaceuticals; is a consultant for Avanir Pharmaceuticals, Sanofi-aventis, Athena Diagnostics and UCB; receives research support from UCB, Biogen, Cytokinetics, Neuraltis and NIH. His clinic is sponsored by the ALS Association; and he is also involved in conducting clinical trials.

1) Patients treated with antiepileptic drugs and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. John Wark and Prof. Terry O' Brien about their paper on falls and fractures in patients treated with antiepileptic drugs. Dr. Jennifer Fugate is reading our e-Pearl of the week about Duchenne muscular dystrophy. In the next part of the podcast Dr. Alberto Espay continues his interview with Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with interviews from other plenary sessions. All participants have disclosures.Dr. Fountain serves as an editorial board member of Epilepsy Currents, serves on the Board of Directors, National Association of Epilepsy Centers, receives travel reimbursement from UCB; performs EEG interpretation for the University of Virginia (10% effort); receives research support from UCB, Sepracor Inc., Medtronic, Inc., Vertex Pharmaceuticals and NeuroPace; and is funded by the NIH.Dr. Wark serves on the scientific advisory boards for Amgen/GlaxoSmithKline, Novartis and LactoPharma; serves as a specialist editor of Clinical Science; editorial board members of Osteoporosis International and Journal of Osteoporosis; serves on the speakers' bureau of Servier, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; serves on the speakers' bureau of Servier, Amgen, Novartis, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; received travel reimbursement from Servier; is a consultant for Vactec and AstraZeneca; performs bone density testing for the Royal Melbourne Hospital (10% effort); receives royalties from the publication of the book Physical Activity and Bone Health; receives research support from Novartis, UCB, Sanofi-aventis, Eli Lilly and Company, Monash University, LaTrobe University, National Health and Medical Research Council of Australia, Victorian Cancer Agency and ANZ Trustees.Prof. O'Brien served as editorial board members of Epilepsia, Journal of Clinical Neuroscience and Epilepsy and Behavior; serves on the speakers' bureaus of UCB, Sanofi-aventis and SiGen and receives research support from UCB, Sanofi-aventis Jansen-Cilag, Royal Melbourne Hospital Neuroscience Foundation and Epilepsy Research Foundation and is funded by the NIH and NHMRC.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.

1) Bleeding risk after stroke thrombolysis and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Michael Knoflach about his paper on an increased bleeding risk after stroke thrombolysis. Dr. Jennifer Fugate is reading our e-Pearl of the week about hummingbird sign in PSP. In the next part of the podcast Dr. Alberto Espay interviews Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with our interview with Drs. Titulaer and Vincent. The participants had nothing to disclose except Drs. Kissela, Kiechl, Fugate, Espay and Mehler.Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH, and provides medico-legal reviews.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.